

Supporting Information

A new method for α -specific glucosylation and its application to one-pot synthesis of a branched α -glucan

Yanxin Zhang,^a Shihao Zhou,^a Xiaohan Wang,^a Han Zhang,^a Zhongwu Guo^{*ab} and Jian Gao^{*a}

- a. National Glycoengineering Research Center, Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, Shandong University, 72 Binhai Road, Qingdao, Shandong 266237, China
- b. Department of Chemistry, University of Florida, 214 Leigh Hall, Gainesville, Florida 32611, United State

* Corresponding author. E-mail: zguo@chem.ufl.edu; E-mail: jgao@sdu.edu.cn

Table of Contents


I. Experimental procedures -----	S2-24
II. NMR spectra of synthetic intermediates and final products-----	S25-75

I. Experimental procedures

General methods: Chemical and materials were purchased from commercial sources and were used as received without further purification unless otherwise noted. Molecular sieve 4Å was flame-dried under high vacuum and cooled under an Argon atmosphere immediately before use. Analytical TLC was carried out on Silica Gel 60Å F254 plates with detection by a UV detector and/or by charring with 15% H₂SO₄ in EtOH (w/v). Mass spectrometry (MS) was performed on a high resolution ESI-TOF MS machine. NMR spectra were recorded on a 500 or 600 MHz machine with chemical shifts reported in ppm (δ) downfield from internal tetramethylsilane (TMS) reference. Signals are described as s (singlet), d (doublet), t (triplet), or m (multiplet), and the coupling constants are reported in Hz.


General procedures for preactivation-based glucosylation: A mixture of donor (0.10 mmol, 1.0 equiv) and freshly activated MS 4Å in anhydrous Et₂O (5 mL) was stirred at room temperature under Argon atmosphere for 1.0 h and then cooled to -78 °C. A solution of AgOTf (25.7 mg, 0.10 mmol, 1.0 equiv) in Et₂O (0.2 mL) was added to the reaction mixture. After stirring for fifteen minutes, *p*-TolSCl (14.5 μ L, 0.10 mmol, 1.0 equiv) was added to the reaction mixture through a microsyringe without touching the flask. Fifteen minutes later, a solution of acceptor (0.09 mmol, 0.9 equiv) in Et₂O (0.5 mL), which was precooled to -78 °C, was added to the reaction mixture dropwise. The reaction solution was allowed to warm up to room temperature slowly in 1.5 h and stirred for another 15 min. The reaction mixture was then quenched with Et₃N, diluted with CH₂Cl₂ (50 mL), and filtered. The filtrate was concentrated under vacuum, and the residue purified by silica gel column chromatography to give product.

p-Tolyl 2,3,4,6-tetra-*O*-benzyl-D-glucopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-benzyl-1-thio- β -D-glucopyranoside (**19**)




Donor **1** reacted with acceptor **5** by the general procedure for glycosylation to give product **19** (86 mg, 89% yield) as syrup after column purification (hexanes/ethyl acetate, 14:1): α/β = 4:1 as determined by integrations of H-1' and SPhCH₃ signals with the stereochemistry determine by $J_{H1',H2'}$ coupling constant. α -**19**:

¹H NMR (600 MHz, CDCl₃) δ : 7.56 – 7.00 (m, 39H, Ph), 5.64 (d, J = 3.6 Hz, 1H, H-1'), 4.93 – 4.67 (m, 6H, Bn), 4.62 (d, J = 10.2 Hz, 1H, H-1), 4.60 – 4.43 (m, 7H, Bn), 4.31 (d, J = 12.0 Hz, 1H, Bn), 4.09 (t, J = 9.0 Hz, 1H, H-4), 3.95 – 3.83 (m, 2H, H-3', H-6a), 3.82 – 3.72 (m, 3H, H-3, H-5', H-6b), 3.68 – 3.62 (m, 1H, H-4'), 3.60 – 3.48 (m, 4H, H-2, H-2', H-5, H-6a'), 3.44 – 3.31 (m, 1H, H-6b'), 2.32 (s, 3H, PhCH₃). ¹³C NMR (150 MHz, CDCl₃) δ : 97.05 (C-1'), 87.34 (C-1), 86.78, 82.02, 80.86, 79.28, 78.70, 77.68, 72.52, 71.00, 69.10, 68.15, 21.15 (PhCH₃). HR ESI-TOF MS (m/z): calcd for C₆₈H₇₄NO₁₀S [M + NH₄]⁺, 1096.5033; found, 1096.5024.

p-Tolyl**2,3,4,6-tetra-O-benzyl-D-glucopyranosyl-(1→6)-2,3,4-tri-O-benzyl-1-thio-β-D-glucopyranoside (20)**


Donor **1** reacted with acceptor **6** by the general procedure for glycosylation to give product **20** (83 mg, 86% yield) as a syrup after column purification (hexanes/ethyl acetate, 14:1): $\alpha/\beta = 5:1$ as determined by integrations of H-1' and SPhCH₃ signals with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. α -**20** (G. Wasonga, Y. Zeng, X. Huang, *Sci. China Chem.* **2011**, *54*, 66-73): ¹H NMR (600 MHz, CDCl₃) δ : 7.49 – 7.00

(m, 39H, Ph), 5.04 (d, $J = 3.6$ Hz, 1H, H-1'), 5.01 – 4.71 (m, 8H, Bn), 4.69 – 4.41 (m, 7H, Bn, H-1), 4.00 (t, $J = 9.6$ Hz, 1H, H-3'), 3.90 – 3.87 (m, 1H, H-5'), 3.85 (dd, $J = 12.0, 4.8$ Hz, 1H, H-6a), 3.78 (d, $J = 12.0$ Hz, 1H, H-6b), 3.74 – 3.59 (m, 6H, H-3, H-2', H-4, H-4', H-6a', H-6b'), 3.51 – 3.46 (m, 1H, H-5), 3.26 (t, $J = 9.0$ Hz, 1H, H-2), 2.22 (s, 3H, PhCH₃). HR ESI-TOF MS (m/z): calcd for C₆₈H₇₄NO₁₀S [M + NH₄]⁺, 1096.5033; found, 1096.5046.

Methyl 2,3,4,6-tetra-O-benzyl-D-glucopyranosyl-(1→4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside (21)

Donor **1** reacted with acceptor **7** by the general procedure for glycosylation to give product **21** (83 mg, 93% yield) as a syrup after column purification (hexanes/ethyl acetate, 13:1): $\alpha/\beta = 3:1$ as determined by integrations of H-1' and OCH₃ signals with the

stereochemistry determined by $J_{H1',H2'}$ coupling constant. α -**21**: ¹H NMR (600 MHz, CDCl₃) δ : 7.50 – 7.05 (m, 35H, Ph), 5.73 (d, $J = 3.6$ Hz, 1H, H-1'), 5.07 (d, $J = 11.4$ Hz, 1H, Bn), 4.94 – 4.76 (m, 4H, Bn), 4.73 (d, $J = 12.0$ Hz, 1H, Bn), 4.67 – 4.50 (m, 6H, Bn, H-1), 4.48 – 4.38 (m, 2H, Bn), 4.30 (d, $J = 12.0$ Hz, 1H, Bn), 4.14 – 4.05 (m, 2H, H-3, H-4), 3.94 (t, $J = 9.6$ Hz, 1H, H-3'), 3.90 – 3.82 (m, 2H, H-5, H-6a), 3.76 – 3.60 (m, 4H, H-2, H-4', H-5', H-6b), 3.58 – 3.48 (m, 2H, H-2', H-6a'), 3.43 – 3.41 (m, 1H, H-6b'), 3.40 (s, 3H, OCH₃). ¹³C NMR (150 MHz, CDCl₃) δ : 97.78 (C-1), 96.65 (C-1'), 82.07, 82.05, 80.21, 79.46, 77.64, 72.27, 70.97, 69.53, 69.02, 68.15, 55.17 (OCH₃). HR ESI-TOF MS (m/z): calcd for C₆₂H₇₀NO₁₁ [M + NH₄]⁺, 1004.4949; found, 1004.4943.


Methyl 2,3,4,6-tetra-O-benzyl-D-glucopyranosyl-(1→6)-2,3,4-tri-O-benzyl-α-D-glucopyranoside (22)

Donor **1** reacted with acceptor **8** by the general procedure for glycosylation to give product **22** (80 mg, 90% yield) as a syrup after column purification (hexanes/ethyl acetate, 13:1): $\alpha/\beta = 2:1$ as determined by integrations of H-1' and OCH₃ signals with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. α -**22** (G. Wasonga, Y. Zeng, X. Huang, *Sci. China Chem.* **2011**, *54*, 66-73.): ¹H NMR (600 MHz, CDCl₃) δ : 7.37 – 7.10 (m, 35H, Ph), 4.98 (d, $J =$

3.6 Hz, 1H, H-1'), 4.98 – 4.90 (m, 3H, Bn), 4.84 – 4.79 (m, 2H, Bn), 4.77 (d, $J = 12.0$ Hz, 1H, Bn), 4.71

(d, $J = 12.0$ Hz, 1H, Bn), 4.68 – 4.63 (m, 3H, Bn), 4.61 – 4.55 (m, 2H, Bn), 4.55 (d, $J = 3.6$ Hz, 1H, H-1), 4.45 (d, $J = 10.8$ Hz, 1H, Bn), 4.42 (d, $J = 12.0$ Hz, 1H, Bn), 4.01 – 3.94 (m, 2H, H-3, H-3'), 3.83 – 3.75 (m, 3H, H-5, H-5', H-6a'), 3.74 – 3.70 (m, 1H, H-6a), 3.69 – 3.61 (m, 3H, H-4, H-4', H-6b'), 3.57 – 3.55 (m, 1H, H-6b), 3.54 (dd, $J = 9.6, 3.6$ Hz, 1H, H-2'), 3.44 (dd, $J = 9.6, 3.6$ Hz, 1H, H-2), 3.35 (s, 3H, OCH_3). HR ESI-TOF MS (m/z): calcd for $\text{C}_{62}\text{H}_{70}\text{NO}_{11}$ [$\text{M} + \text{NH}_4$] $^+$, 1004.4949; found, 1004.4947.

***p*-Tolyl 4,6-*O*-benzylidene-2,3-di-*O*-benzyl-D-glucopyranosyl-(1→4)-2,3,6-tri-*O*-benzyl-1-thio-β-D-glucopyranoside (23)**




23

Donor **2** reacted with acceptor **5** by the general procedure for glycosylation to give product **23** (81 mg, 91% yield) as a syrup after column purification (hexanes/ethyl acetate, 15:1): $\alpha/\beta = 4:1$ as determined by integrations of H-1' and SPhCH_3 signals with

the stereochemistry determine by $J_{\text{H}1',\text{H}2'}$ coupling constant. α -**23**: ^1H NMR (600 MHz, CDCl_3) δ : 7.80 – 6.95 (m, 34H, Ph), 5.67 (d, $J = 3.6$ Hz, 1H, H-1'), 5.53 (s, 1H, PhCH), 4.92 – 4.78 (m, 4H, Bn), 4.74 – 4.66 (m, 3H, Bn), 4.62 – 4.50 (m, 4H, Bn, H-1), 4.16 – 4.10 (m, 2H, H-4, H-6a'), 3.99 (t, $J = 9.6$ Hz, 1H, H-3'), 3.91 – 3.78 (m, 4H, H-3, H-5, H-6a,6b), 3.64 – 3.55 (m, 3H, H-4', H-5', H-6b'), 3.54 – 3.47 (m, 2H, H-2, H-2'), 2.32 (s, 3H, PhCH_3). ^{13}C NMR (150 MHz, CDCl_3) δ : 101.11 (PhCH), 97.49 (C-1'), 87.28 (C-1), 86.91, 82.30, 80.84, 78.75, 78.61, 78.37, 71.62, 68.89, 65.57, 63.30, 21.14 (PhCH_3). HR ESI-TOF MS (m/z): calcd for $\text{C}_{61}\text{H}_{66}\text{NO}_{10}\text{S}$ [$\text{M} + \text{NH}_4$] $^+$, 1004.4407; found, 1004.4415.

***p*-Tolyl 4,6-*O*-benzylidene-2,3-di-*O*-benzyl-D-glucopyranosyl-(1→6)-2,3,4-tri-*O*-benzyl-1-thio-β-D-glucopyranoside (24)**




24

Donor **2** reacted with acceptor **6** by the general procedure for glycosylation to give product **24** (78 mg, 88% yield) as a syrup after column purification (hexanes/ethyl acetate, 15:1): $\alpha/\beta = 5:1$ as determined by integrations of H-1' and SPhCH_3 signals with the stereochemistry determine by $J_{\text{H}1',\text{H}2'}$ coupling constant. α -**24**: ^1H NMR (600 MHz, CDCl_3) δ : 7.71 – 6.89 (m, 34H, Ph), 5.58 (s, 1H, PhCH),

5.05 (d, $J = 3.6$ Hz, 1H, H-1'), 4.95 – 4.74 (m, 8H, Bn), 4.70 – 4.56 (m, 3H, Bn, H-1), 4.30 (dd, $J = 10.2, 4.8$ Hz, 1H, H-6a'), 4.04 (t, $J = 9.6$ Hz, 1H, H-3'), 3.98 – 3.91 (m, 1H, H-5'), 3.87 (dd, $J = 12.0, 4.2$ Hz, 1H, H-6a), 3.80 (dd, $J = 12.0, 1.8$ Hz, 1H, H-6b), 3.76 – 3.62 (m, 4H, H-3, H-4', H-5, H-6b'), 3.61 – 3.57 (m, 1H, H-2'), 3.53 – 3.44 (m, 1H, H-4), 3.26 (t, $J = 9.6$ Hz, 1H, H-2), 2.23 (s, 3H, PhCH_3). ^{13}C NMR (150 MHz, CDCl_3) δ : 101.36 (PhCH), 98.26 (C-1'), 88.39 (C-1), 86.65, 82.18, 81.12, 79.56, 78.83, 78.03, 77.40, 69.14, 66.20, 62.61, 21.06 (PhCH_3). HR ESI-TOF MS (m/z): calcd for $\text{C}_{61}\text{H}_{66}\text{NO}_{10}\text{S}$ [$\text{M} + \text{NH}_4$] $^+$, 1004.4407; found, 1004.4419.


Methyl 4,6-*O*-benzylidene-2,3-di-*O*-benzyl-D-glucopyranosyl-(1→4)-2,3,6-tri-*O*-benzyl-α-D-glucopyranoside (25)



Donor **2** reacted with acceptor **7** by the general procedure for glycosylation to give product **25** (74 mg, 92% yield) as a syrup after column purification (hexanes/ethyl acetate, 15:1): $\alpha/\beta = 3:1$ as determined by integrations of H-1' and OCH₃ signals with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. α -**25**: ¹H


NMR (600 MHz, CDCl₃) δ : 7.68 – 7.06 (m, 30H, Ph), 5.78 (d, $J = 3.6$ Hz, 1H, H-1'), 5.56 (s, 1H, PhCH), 5.07 (d, $J = 12.0$ Hz, 1H, Bn), 4.93 (d, $J = 11.4$ Hz, 1H, Bn), 4.85 – 4.76 (m, 2H, Bn), 4.74 – 4.67 (m, 3H, Bn), 4.65 (d, $J = 3.6$ Hz, 1H, H-1), 4.63 – 4.55 (m, 3H, Bn), 4.24 – 4.10 (m, 3H, H-3, H-4, H-6a'), 4.02 (t, $J = 9.6$ Hz, 1H, H-3'), 3.94 – 3.83 (m, 3H, H-5, H-5', H-6a), 3.73 – 3.67 (m, 1H, H-6b), 3.66 – 3.61 (m, 3H, H-2, H-4', H-6b'), 3.57 – 3.51 (m, 1H, H-2'), 3.41 (s, 3H, OCH₃). ¹³C NMR (150 MHz, CDCl₃) δ : 101.12 (PhCH), 97.74 (C-1), 97.19 (C-1'), 82.31, 82.13, 80.26, 78.86, 78.76, 71.61, 69.34, 68.94, 68.79, 63.29, 55.20 (OCH₃). HR ESI-TOF MS (m/z): calcd for C₅₅H₆₂NO₁₁ [M + NH₄]⁺, 912.4323; found, 912.4343.

Methyl 4,6-O-benzylidene-2,3-di-O-benzyl-D-glucopyranosyl-(1→6)-2,3,4-tri-O-benzyl- α -D-glucopyranoside (26)



Donor **2** reacted with acceptor **8** by the general procedure for glycosylation to give product **26** (72 mg, 90% yield) as a syrup after column purification (hexanes/ethyl acetate, 15:1): $\alpha/\beta = 6:1$ as determined by integrations of H-1' and OCH₃ signals with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. α -**26**: ¹H NMR (600 MHz, CDCl₃) δ : 7.50 – 7.15 (m, 30H, Ph), 5.53 (s, 1H, PhCH), 4.97 (d, $J = 10.8$ Hz, 1H, Bn), 4.92 (d, $J = 3.6$ Hz, 1H, H-1'), 4.91 – 4.86 (m, 2H, Bn), 4.83 – 4.79 (m, 2H, Bn), 4.75 – 4.65 (m, 3H, Bn), 4.63 (d, $J = 10.8$ Hz, 1H, Bn), 4.59 – 4.55 (m, 2H, H-1, Bn), 4.20 (dd, $J = 10.2, 4.8$ Hz, 1H, H-6a'), 4.02 – 3.96 (m, 2H, H-3, H-3'), 3.91 – 3.86 (m, 1H, H-5'), 3.81 – 3.66 (m, 4H, H-5, H-6a, H-6b, H-6b'), 3.64 – 3.56 (m, 2H, H-4, H-4'), 3.53 (dd, $J = 9.6, 3.6$ Hz, 1H, H-2), 3.43 (dd, $J = 9.6, 3.6$ Hz, 1H, H-2'), 3.34 (s, 3H, OCH₃). ¹³C NMR (150 MHz, CDCl₃) δ : 101.27 (PhCH), 98.18 (C-1'), 97.96 (C-1), 82.15, 82.08, 80.03, 79.28, 77.90, 77.70, 70.33, 69.07, 66.32, 62.51, 55.19 (OCH₃). HR ESI-TOF MS (m/z): calcd for C₅₅H₆₂NO₁₁ [M + NH₄]⁺, 912.4323; found, 912.4340.


***p*-Tolyl 2,3,4-tri-O-benzyl-6-O-*tert*-butyldimethylsilyl- α -D-glucopyranosyl-(1→4)-2,3,6-tri-O-benzyl-1-thio- β -D-glucopyranoside (27)**



Donor **3** reacted with acceptor **5** by the general procedure for glycosylation to give product **27** (88 mg, 89% yield) as a syrup after column purification (hexanes/ethyl acetate, 14:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. ¹H NMR (600 MHz, CDCl₃) δ : 7.54 – 7.50 (m, 2H, Ph), 7.41 – 7.00 (m, 32H, Ph), 5.56 (d, $J = 3.6$ Hz, 1H, H-1'), 4.91 – 4.84 (m, 5H, Bn), 4.80 (d, $J = 10.8$ Hz, 1H, Bn), 4.68 (d, $J = 10.8$ Hz, 1H, Bn), 4.64 (d, $J = 9.6$ Hz, 1H, H-1), 4.62 – 4.56 (m, 4H, Bn), 4.52 (d, J

= 12.0 Hz, 1H, Bn), 4.10 (t, J = 9.0 Hz, 1H, H-4), 3.98 – 3.89 (m, 2H, H-3', H-6a), 3.87 – 3.78 (m, 2H, H-3, H-6b), 3.72 (dd, J = 11.4, 3.0 Hz, 1H, H-6a'), 3.70 – 3.61 (m, 3H, H-4', H-5', H-6b'), 3.61 – 3.54 (m, 2H, H-2, H-5), 3.42 (dd, J = 9.6, 3.6 Hz, 1H, H-2'), 2.33 (s, 3H, PhCH₃), 0.89 (s, 9H, *t*Bu), 0.03 (s, 3H, SiCH₃), 0.02 (s, 3H, SiCH₃). ¹³C NMR (150 MHz, CDCl₃) δ : 138.71, 138.69, 138.67, 138.50, 138.00, 137.96, 137.69, 132.74, 129.68, 129.61, 128.38, 128.36, 128.29, 128.26, 127.98, 127.86, 127.69, 127.65, 127.58, 127.55, 127.38, 127.35, 127.17, 126.54, 96.57 (C-1'), 87.36 (C-1), 86.84, 81.86, 80.77, 79.85, 78.71, 77.56, 77.25, 77.04, 76.83, 75.67, 75.19, 75.02, 74.19, 73.35, 73.17, 72.44, 72.28, 69.21, 61.86, 25.98, 21.16, 18.35, -5.05, -5.34. HR ESI-TOF MS (m/z): calcd for C₆₇H₈₂NO₁₀SSi [M + NH₄]⁺, 1120.5429; found, 1120.5447.


***p*-Tolyl 2,3,4-tri-*O*-benzyl-6-*O*-*tert*-butyldimethylsilyl- α -D-glucopyranosyl-(1 \rightarrow 6)-2,3,4-tri-*O*-benzyl-1-thio- β -D-glucopyranoside (28)**



Donor **3** reacted with acceptor **6** by the general procedure for glycosylation to give product **28** (86 mg, 87% yield) as a syrup after column purification (hexanes/ethyl acetate, 14:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. ¹H NMR (600 MHz, CDCl₃) δ : 7.48 (d, J = 8.4 Hz, 2H, Ph), 7.43 – 7.22 (m, 30H, Ph), 7.09 (d, J = 7.8 Hz, 2H, Ph), 5.05 (d, J = 3.6 Hz, 1H, H-1'), 4.97 (d, J =

10.8 Hz, 1H, Bn), 4.92 (d, J = 11.4 Hz, 1H, Bn), 4.90 – 4.86 (m, 2H, Bn), 4.85 – 4.80 (m, 3H, Bn), 4.78 (d, J = 12.0 Hz, 1H, Bn), 4.74 – 4.67 (m, 3H, Bn), 4.63 (d, J = 10.2 Hz, 1H, Bn), 4.56 (d, J = 9.6 Hz, 1H, H-1), 4.01 (t, J = 9.6 Hz, 1H, H-3'), 3.87 – 3.82 (m, 2H, H-6a, H-6a'), 3.81 – 3.77 (m, 2H, H-6b, H-6b'), 3.77 – 3.73 (m, 1H, H-5'), 3.71 (t, J = 9.6 Hz, 1H, H-4), 3.68 – 3.60 (m, 2H, H-3, H-4'), 3.54 (dd, J = 9.6, 3.6 Hz, 1H, H-2'), 3.49 – 3.45 (m, 1H, H-5), 3.26 (t, J = 9.6 Hz, 1H, H-2), 2.23 (s, 3H, PhCH₃), 0.91 (s, 9H, *t*Bu), 0.08 (s, 3H, SiCH₃), 0.07 (s, 3H, SiCH₃). ¹³C NMR (150 MHz, CDCl₃) δ : 138.81, 138.72, 138.56, 138.51, 138.19, 138.07, 137.91, 133.27, 129.76, 129.67, 128.44, 128.43, 128.41, 128.38, 128.37, 128.32, 128.26, 128.14, 127.90, 127.84, 127.76, 127.72, 127.68, 127.59, 127.55, 127.52, 127.48, 97.03 (C-1'), 88.17 (C-1), 86.65, 81.73, 81.08, 80.57, 78.96, 77.58, 77.54, 75.78, 75.63, 75.46, 74.99, 74.95, 72.41, 71.65, 65.74, 62.17, 25.98, 21.08, 18.35, -5.05, -5.32. HR ESI-TOF MS (m/z): calcd for C₆₇H₈₂NO₁₀SSi [M + NH₄]⁺, 1120.5429; found, 1120.5442.


Methyl 2,3,4-tri-*O*-benzyl-6-*O*-*tert*-butyldimethylsilyl- α -D-glucopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-benzyl- α -D-glucopyranoside (29)



Donor **3** reacted with acceptor **7** by the general procedure for glycosylation to give product **29** (86 mg, 94% yield) as a syrup after column purification (hexanes/ethyl acetate, 14:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. ¹H NMR (600 MHz, CDCl₃) δ : 7.52 – 6.97 (m, 30H, Ph), 5.61 (d, J = 3.6 Hz, 1H, H-1'), 5.03 (d, J = 11.4 Hz, 1H, Bn), 4.89 – 4.83 (m, 2H, Bn), 4.83 – 4.76 (m, 2H, Bn), 4.71 (d, J

= 12.0 Hz, 1H, Bn), 4.65 (d, J = 10.8 Hz, 1H, Bn), 4.62 (d, J = 3.6 Hz, 1H, H-1), 4.60 – 4.50 (m, 5H, Bn), 4.08 – 4.05 (m, 2H, H-3, H-4), 3.92 (t, J = 8.4 Hz, 1H, H-3'), 3.88 – 3.83 (m, 2H, H-5', H-6a), 3.69 – 3.57 (m, 6H, H-2', H-4', H-5, H-6b, H-6a', 6b'), 3.40 (dd, J = 10.2, 3.6 Hz, 1H, H-2), 3.38 (s, 3H, OCH₃), 0.86 (s, 9H, *t*Bu), -0.01 (s, 6H, SiCH₃). ¹³C NMR (150 MHz, CDCl₃) δ : 139.07, 138.78, 138.74, 138.12, 138.03, 138.00, 128.41, 128.34, 128.32, 128.29, 128.22, 128.18, 128.00, 127.90, 127.80, 127.77, 127.58, 127.55, 127.36, 127.23, 127.03, 126.68, 97.74 (C-1), 96.04 (C-1'), 82.07, 81.88, 80.14, 79.95, 77.50, 75.69, 74.97, 74.19, 73.34, 73.16, 73.11, 72.17, 71.98, 69.42, 69.05, 61.84, 55.12, 25.95, 18.31, -5.07, -5.38. HR ESI-TOF MS (m/z): calcd for C₆₁H₇₈NO₁₁Si [M + NH₄]⁺, 1028.5344; found, 1028.5355.


Methyl 2,3,4-tri-*O*-benzyl-6-*O*-*tert*-butyldimethylsilyl- α -D-glucopyranosyl-(1 \rightarrow 6)-2,3,4-tri-*O*-benzyl- α -D-glucopyranoside (30)



Donor **3** reacted with acceptor **8** by the general procedure for glycosylation to give product **30** (83 mg, 91% yield) as a syrup after column purification (hexanes/ethyl acetate, 14:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. ¹H NMR (600 MHz, CDCl₃) δ : 7.69 – 7.00 (m, 30H, Ph), 5.00 (d, J = 10.2 Hz, 1H, Bn), 4.99 (d, J = 4.2 Hz, 1H, H-1'), 4.98 – 4.89 (m, 3H, Bn), 4.85 (d, J = 10.8 Hz, 1H, Bn), 4.81 (d, J = 10.2 Hz, 1H, Bn), 4.77 – 4.64 (m, 5H, Bn), 4.59 (d, J = 12.0 Hz, 1H, Bn), 4.58 (d, J = 3.6 Hz, 1H, H-1), 4.05 – 3.97 (m,

2H, H-3, H-3'), 3.85 (dd, J = 12.0, 4.8 Hz, 1H, H-6a), 3.83 – 3.72 (m, 4H, H-5', H-6b, H-6a', 6b'), 3.72 – 3.67 (m, 2H, H-4', H-5), 3.58 (t, J = 9.6 Hz, 1H, H-4), 3.52 (dd, J = 9.6, 3.6 Hz, 1H, H-2'), 3.46 (dd, J = 9.6, 3.6 Hz, 1H, H-2), 3.38 (s, 3H, OCH₃), 0.90 (s, 9H, *t*Bu), 0.05 (s, 3H, SiCH₃), 0.04 (s, 3H, SiCH₃). ¹³C NMR (150 MHz, CDCl₃) δ : 138.85, 138.79, 138.73, 138.58, 138.43, 138.21, 128.43, 128.39, 128.37, 128.35, 128.17, 128.03, 128.00, 127.85, 127.81, 127.69, 127.65, 127.57, 127.56, 127.53, 97.97 (C-1), 97.04 (C-1'), 82.15, 81.71, 80.40, 80.14, 77.80, 77.62, 75.74, 75.63, 75.03, 74.87, 73.42, 72.35, 71.67, 70.47, 65.74, 62.20, 55.14, 25.95, 18.32, -5.10, -5.35. HR ESI-TOF MS (m/z): calcd for C₆₁H₇₈NO₁₁Si [M + NH₄]⁺, 1028.5344; found, 1028.5348.

***p*-Tolyl 2,3,4-tri-*O*-benzyl-6-*O*-*tert*-butyldimethylsilyl- α -D-glucopyranosyl-(1 \rightarrow 3)-4,6-*O*-benzylidene-2-*O*-benzyl-1-thio- β -D-glucopyranoside (31)**




31

Donor **3** reacted with acceptor **9** by the general procedure for glycosylation to give product **31** (78 mg, 86% yield) as a syrup after column purification (hexanes/ethyl acetate, 14:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. ¹H NMR (600 MHz, CDCl₃) δ : 7.54 – 6.92 (m, 29H, Ph), 5.59 (d, J = 3.6

Hz, 1H, H-1'), 5.49 (s, 1H, PhCH), 5.02 – 4.95 (m, 2H, Bn), 4.92 (d, J = 10.8 Hz, 1H, Bn), 4.84 (d, J = 10.8 Hz, 1H, Bn), 4.75 (d, J = 10.2 Hz, 1H, H-1), 4.70 (d, J = 9.6 Hz, 1H, Bn), 4.65 – 4.56 (m, 2H, Bn), 4.43 – 4.32 (m, 2H, H-6a, Bn), 4.17 (t, J = 9.6 Hz, 1H, H-3), 4.02 (t, J = 9.6 Hz, 1H, H-3'), 3.95 – 3.91 (m, 1H, H-5'), 3.88 – 3.76 (m, 2H, H-4, H-6b), 3.65 (t, J = 9.6 Hz, 1H, H-4'), 3.58 (t, J = 10.2 Hz, 1H, H-2),

3.55 – 3.51 (m, 1H, H-5), 3.46 – 3.41 (m, 3H, H-2', H-6a',6b'), 2.38 (s, 3H, PhCH₃), 0.83 (s, 9H, *t*Bu), -0.06 (s, 3H, SiCH₃), -0.07 (s, 3H, SiCH₃). ¹³C NMR (150 MHz, CDCl₃) δ: 139.05, 138.79, 138.24, 137.85, 137.32, 136.91, 132.85, 129.88, 129.40, 129.10, 128.80, 128.45, 128.33, 128.23, 128.19, 128.13, 128.07, 127.79, 127.61, 127.54, 127.46, 127.44, 127.37, 126.38, 102.07 (PhCH), 96.03 (C-1'), 88.76 (C-1), 82.22, 81.84, 79.16, 78.92, 77.14, 76.64, 75.84, 75.76, 74.86, 71.42, 70.95, 69.83, 68.87, 61.40, 26.01, 21.18, 18.27, -5.25, -5.47. HR ESI-TOF MS (*m/z*): calcd for C₆₀H₇₄NO₁₀SSi [M + NH₄]⁺, 1028.4803; found, 1028.4832.

***p*-Tolyl 6-O-benzoyl-2,3,4-tri-O-benzyl-α-D-glucopyranosyl-(1→4)-2,3,6-tri-O-benzyl-1-thio-β-D-glucopyranoside (32)**




32

Donor **4** reacted with acceptor **5** by the general procedure for glycosylation to give product **32** (87 mg, 88% yield) as a syrup after column purification (hexanes/ethyl acetate, 12:1) with the stereochemistry determined by *J*_{H1',H2'} coupling constant. ¹H NMR (600 MHz, CDCl₃) δ: 8.03 – 7.99 (m, 2H, Ph), 7.60 – 7.03 (m, 37H, Ph), 5.56

(d, *J* = 3.6 Hz, 1H, H-1'), 4.92 – 4.88 (m, 4H, Bn), 4.85 (d, *J* = 10.2 Hz, 1H, Bn), 4.80 (d, *J* = 10.8 Hz, 1H, Bn), 4.64 (d, *J* = 9.6 Hz, 1H, H-1), 4.61 – 4.56 (m, 5H, Bn), 4.52 (d, *J* = 12.0 Hz, 1H, Bn), 4.41 – 4.39 (m, 2H, H-6a',6b'), 4.10 (t, *J* = 9.6 Hz, 1H, H-4), 4.06 – 4.02 (m, 1H, H-5'), 3.99 (t, *J* = 9.6 Hz, 1H, H-3'), 3.89 (dd, *J* = 11.4, 4.2 Hz, 1H, H-6a), 3.82 – 3.78 (m, 2H, H-3, H-6b), 3.62 – 3.55 (m, 2H, H-4', H-5), 3.52 (t, *J* = 9.6 Hz, 1H, H-2), 3.49 (dd, *J* = 9.6, 3.6 Hz, 1H, H-2'), 2.33 (s, 3H, PhCH₃). ¹³C NMR (150 MHz, CDCl₃) δ: 166.13, 138.67, 138.37, 138.18, 137.86, 137.83, 137.77, 133.02, 132.75, 129.97, 129.70, 129.68, 129.60, 128.46, 128.43, 128.39, 128.36, 128.32, 128.30, 128.27, 128.23, 128.09, 127.97, 127.95, 127.92, 127.85, 127.72, 127.63, 127.60, 127.51, 127.11, 126.44, 96.64 (C-1'), 87.51 (C-1), 86.57, 81.90, 80.75, 79.68, 78.74, 77.73, 75.76, 75.22, 74.13, 73.36, 73.28, 73.10, 69.64, 68.97, 63.42, 21.16. HR ESI-TOF MS (*m/z*): calcd for C₆₈H₇₂NO₁₁S [M + NH₄]⁺, 1110.4826; found, 1110.4823.

***p*-Tolyl 6-O-benzoyl-2,3,4-tri-O-benzyl-α-D-glucopyranosyl-(1→6)-2,3,4-tri-O-benzyl-1-thio-β-D-glucopyranoside (33)**




33

Donor **4** reacted with acceptor **6** by the general procedure for glycosylation to give product **33** (86 mg, 87% yield) as a syrup after column purification (hexanes/ethyl acetate, 12:1) with the stereochemistry determined by *J*_{H1',H2'} coupling constant. ¹H NMR (600 MHz, CDCl₃) δ: 8.02 (d, *J* = 7.8 Hz, 2H), 7.60 – 7.17 (m, 35H, Ph), 7.06 (d, *J* = 7.8 Hz, 2H, Ph), 5.03 (d, *J* = 3.0 Hz, 1H, H-1'), 5.02 (d, *J* = 11.4

Hz, 1H, Bn), 4.92 (d, *J* = 10.8 Hz, 1H, Bn), 4.91 – 4.86 (m, 2H, Bn), 4.86 – 4.79 (m, 4H, Bn), 4.74 (d, *J* = 12.0 Hz, 1H, Bn), 4.68 – 4.59 (m, 3H, Bn), 4.57 (d, *J* = 9.6 Hz, 1H, H-1), 4.54 (dd, *J* = 12.6, 1.8 Hz, 1H, H-6a'), 4.47 (dd, *J* = 12.0, 4.2 Hz, 1H, H-6b'), 4.08 – 4.05 (m, 1H, H-5'), 4.05 (t, *J* = 9.0 Hz, 1H, H-3'), 3.85 (dd, *J* = 11.4, 4.8 Hz, 1H, H-6a), 3.76 (dd, *J* = 12.0, 1.8 Hz, 1H, H-6b), 3.71 – 3.61 (m, 3H, H-3, H-

4, H-4'), 3.60 (dd, $J = 9.6, 3.6$ Hz, 1H, H-2'), 3.50 – 3.46 (m, 1H, H-5), 3.24 (t, $J = 9.0$ Hz, 1H, H-2), 2.21 (s, 3H, PhCH_3). ^{13}C NMR (150 MHz, CDCl_3) δ : 166.20, 138.54, 138.52, 138.31, 138.09, 138.03, 137.94, 137.75, 133.02, 132.82, 130.01, 129.96, 129.76, 129.69, 128.49, 128.45, 128.44, 128.39, 128.37, 128.25, 128.16, 127.96, 127.83, 127.81, 127.75, 127.72, 127.66, 127.59, 127.57, 97.06 (C-1'), 88.48 (C-1), 86.62, 81.76, 81.13, 80.30, 78.65, 77.57, 75.89, 75.63, 75.46, 75.13, 75.00, 72.45, 68.92, 66.14, 63.42, 21.05. HR ESI-TOF MS (m/z): calcd for $\text{C}_{68}\text{H}_{72}\text{NO}_{11}\text{S}$ [$\text{M} + \text{NH}_4$] $^+$, 1110.4826; found, 1110.4831.


Methyl 6-O-benzoyl-2,3,4-tri-O-benzyl- α -D-glucopyranosyl-(1 \rightarrow 4)-2,3,6-tri-O-benzyl- α -D-glucopyranoside (34)



Donor **4** reacted with acceptor **7** by the general procedure for glycosylation to give product **34** (81 mg, 90% yield) as a syrup after column purification (hexanes/ethyl acetate, 12:1) with the stereochemistry determined by $J_{\text{H}1',\text{H}2'}$ coupling constant. ^1H NMR (600 MHz, CDCl_3) δ : 8.01 (d, $J = 7.8$ Hz, 2H, Ph), 7.58 – 7.18 (m, 33H, Ph), 5.58 (d, $J = 3.6$ Hz, 1H, H-1'), 5.01 (d, $J = 11.4$ Hz, 1H, Bn), 4.95 – 4.89

(m, 2H, Bn), 4.86 – 4.79 (m, 2H, Bn), 4.70 (d, $J = 12.0$ Hz, 1H, Bn), 4.62 (d, $J = 3.6$ Hz, 1H, H-1), 4.61 – 4.50 (m, 6H, Bn), 4.39 (dd, $J = 12.0, 2.4$ Hz, 1H, H-6a'), 4.34 (dd, $J = 12.0, 4.2$ Hz, 1H, H-6b'), 4.09 (t, $J = 9.0$ Hz, 1H, H-3), 4.04 (t, $J = 9.0$ Hz, 1H, H-4), 4.02 – 3.96 (m, 2H, H-3', H-5'), 3.90 – 3.83 (m, 2H, H-5, H-6a), 3.67 – 3.63 (m, 1H, H-6b), 3.62 – 3.55 (m, 2H, H-2, H-4'), 3.48 (dd, $J = 9.6, 3.6$ Hz, 1H, H-2'), 3.39 (s, 3H, OCH_3). ^{13}C NMR (150 MHz, CDCl_3) δ : 166.10, 139.05, 138.43, 137.96, 137.92, 137.85, 132.99, 130.02, 129.69, 128.45, 128.44, 128.36, 128.34, 128.30, 128.21, 128.18, 128.08, 128.03, 127.94, 127.88, 127.73, 127.69, 127.67, 127.58, 127.55, 127.02, 126.71, 97.79 (C-1), 96.33 (C-1'), 81.92, 81.82, 79.91, 79.78, 77.67, 75.80, 75.19, 74.30, 73.39, 73.36, 73.16, 73.12, 69.56, 68.87, 63.39, 55.18. HR ESI-TOF MS (m/z): calcd for $\text{C}_{62}\text{H}_{68}\text{NO}_{12}$ [$\text{M} + \text{NH}_4$] $^+$, 1018.4742; found, 1018.4752.


Methyl 6-O-benzoyl-2,3,4-tri-O-benzyl- α -D-glucopyranosyl-(1 \rightarrow 6)-2,3,4-tri-O-benzyl- α -D-glucopyranoside (35)



Donor **4** reacted with acceptor **8** by the general procedure for glycosylation to give product **35** (83 mg, 92% yield) as a syrup after column purification (hexanes/ethyl acetate, 12:1) with the stereochemistry determined by $J_{\text{H}1',\text{H}2'}$ coupling constant. ^1H NMR (600 MHz, CDCl_3) δ : 8.02 – 7.91 (m, 2H, Ph), 7.59 – 7.20 (m, 33H, Ph), 4.99 (d, $J = 4.2$ Hz, 1H, H-1'), 4.97 – 4.94 (m, 2H, Bn), 4.94 – 4.90 (m, 2H, Bn), 4.83 – 4.79 (m, 2H, Bn), 4.72 – 4.68 (m, 3H, Bn), 4.63 (d, $J = 11.4$ Hz, 1H, Bn), 4.60 (d, $J = 10.8$ Hz, 1H, Bn), 4.58 (d, $J = 12.0$ Hz, 1H, Bn), 4.56 (d, $J = 3.6$ Hz, 1H, H-1), 4.50 (dd, $J = 12.0, 1.8$ Hz, 1H, H-6a'), 4.39 (dd, $J = 12.0, 4.2$ Hz, 1H, H-6b'), 4.04 – 3.96 (m, 3H, H-3, H-3', H-5'), 3.84 – 3.77 (m, 2H, H-5, H-6a), 3.73 – 3.69 (m, 1H, H-6b), 3.63 – 3.58 (m, 2H, H-4, H-4'), 3.56 (dd, $J = 9.6, 3.6$ Hz, 1H, H-2'), 3.42 (dd, $J = 9.6, 3.6$ Hz, 1H, H-2), 3.36 (s, 3H, OCH_3). ^{13}C NMR (150 MHz, CDCl_3) δ : 166.19, 138.76, 138.46, 138.29, 138.28, 138.11,


137.94, 133.04, 129.91, 129.63, 128.43, 128.41, 128.38, 128.34, 128.21, 128.01, 127.99, 127.93, 127.87, 127.81, 127.73, 127.71, 127.69, 127.61, 127.60, 97.89 (C-1), 96.88 (C-1'), 82.08, 81.69, 80.13, 80.09, 77.79, 77.49, 75.76, 75.74, 75.04, 73.34, 72.46, 70.33, 68.85, 65.99, 63.41, 55.19. HR ESI-TOF MS (m/z): calcd for $C_{62}H_{68}NO_{12}$ [$M + NH_4$] $^+$, 1018.4742; found, 1018.4750.

***p*-Tolyl 6-O-benzoyl-2,3,4-tri-O-benzyl- α -D-glucopyranosyl-(1 \rightarrow 3)-4,6-O-benzylidene-2-O-benzyl-1-thio- β -D-glucopyranoside (36)**




Donor **4** reacted with acceptor **9** by the general procedure for glycosylation to give product **36** (80 mg, 89% yield) as a syrup after column purification (hexanes/ethyl acetate, 12:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. 1H NMR (600 MHz, $CDCl_3$) δ : 7.93 (d, J = 7.2 Hz, 2H, Ph), 7.62 – 6.95 (m, 32H, Ph), 5.61 (d, J = 3.6 Hz, 1H, H-1'), 5.48 (s, 1H, PhCH), 5.09 – 5.05 (m, 2H, Bn), 4.92 (d, J = 10.8 Hz, 1H, Bn), 4.88 (d, J = 10.2 Hz, 1H, Bn), 4.74 (d, J = 9.6 Hz, 1H, H-1), 4.71 (d, J = 10.2 Hz, 1H, Bn), 4.61 (d, J = 12.0 Hz, 1H, Bn), 4.52 (d, J = 10.8 Hz, 1H, Bn), 4.38 (dd, J = 10.2, 4.2 Hz, 1H, H-6a), 4.33 (d, J = 12.0 Hz, 1H, Bn), 4.31 – 4.27 (m, 1H, H-5'), 4.21 – 4.16 (m, 2H, H-3, H-6a'), 4.06 (t, J = 9.6 Hz, 1H, H-3'), 4.02 (dd, J = 12.0, 4.2 Hz, 1H, H-6b'), 3.86 (t, J = 9.6 Hz, 1H, H-4), 3.81 (t, J = 10.2 Hz, 1H, H-6b), 3.61 (t, J = 9.6 Hz, 1H, H-2), 3.57 (t, J = 9.6 Hz, 1H, H-4'), 3.54 – 3.47 (m, 2H, H-2', H-5), 2.40 (s, 3H, PhCH₃). ^{13}C NMR (150 MHz, $CDCl_3$) δ : 166.09, 138.55, 138.32, 138.16, 137.54, 137.09, 136.85, 132.85, 132.82, 129.95, 129.93, 129.72, 129.50, 129.22, 128.66, 128.48, 128.43, 128.34, 128.26, 128.18, 128.11, 128.06, 127.94, 127.74, 127.71, 127.58, 127.51, 126.47, 102.31 (PhCH), 95.88 (C-1'), 89.10 (C-1), 82.07, 81.74, 78.73, 77.58, 76.93, 75.92, 75.88, 75.35, 71.13, 69.88, 68.86, 68.68, 63.00, 21.21. HR ESI-TOF MS (m/z): calcd for $C_{61}H_{64}NO_{11}S$ [$M + NH_4$] $^+$, 1018.4200; found, 1018.4195.

3-Azidopropyl 2,3,4-tri-O-benzyl-6-O-*tert*-butyldimethylsilyl- α -D-glucopyranoside (37)




Donor **3** reacted with acceptor **10** by the general procedure for glycosylation to give product **37** (49 mg, 84% yield) as a syrup after column purification (hexanes/ethyl acetate, 12:1): α/β = 12:1 as determined by integrations of H-1 and TBS signals with the stereochemistry determined by $J_{H1,H2}$ coupling constant. α -**37**: 1H NMR (600 MHz, $CDCl_3$) δ : 7.46 – 7.17 (m, 15H, Ph), 4.96 (d, J = 10.8 Hz, 1H, Bn), 4.88 (d, J = 10.8 Hz, 1H, Bn), 4.82 (d, J = 10.8 Hz, 1H, Bn), 4.78 (d, J = 12.0 Hz, 1H, Bn), 4.72 (d, J = 3.6 Hz, 1H, H-1), 4.66 – 4.62 (m, 2H, Bn), 3.97 (t, J = 9.6 Hz, 1H, H-3), 3.80 – 3.77 (m, 1H, H-6a), 3.75 – 3.70 (m, 1H, H-5), 3.63 – 3.58 (m, 1H, H-6b), 3.54 (t, J = 9.6 Hz, 1H, H-4), 3.50 (dd, J = 9.6, 3.6 Hz, 1H, H-2), 3.47 – 3.34 (m, 4H, OCH_2CH_2 , CH_2N_3), 1.93 – 1.81 (m, 2H, $CH_2CH_2CH_2$), 0.88 (s, 9H, *t*Bu), 0.04 (s, 3H, SiCH₃), 0.03 (s, 3H, SiCH₃). ^{13}C NMR (150 MHz, $CDCl_3$) δ : 138.76, 138.38, 138.30, 128.44, 128.40, 128.33, 128.04, 127.92, 127.88, 127.84, 127.74, 127.62, 96.91 (C-1), 82.03, 80.41, 77.68, 75.80, 75.09, 73.25, 71.75, 64.47, 62.21, 48.38, 28.87, 25.91, 18.30, -5.17, -5.38. HR ESI-TOF MS (m/z): calcd for $C_{36}H_{53}N_4O_6Si$ [$M + NH_4$] $^+$, 665.3734; found, 665.3735.

***p*-Tolyl 2,3,4-tri-*O*-benzyl-6-*O*-*tert*-butyldimethylsilyl- α -D-glucopyranosyl-(1 \rightarrow 6)-4-*O*-benzyl-2,3-di-*O*-isopropylidene-1-thio- α -D-mannopyranoside (**38**)**



Donor **3** reacted with acceptor **11** by the general procedure for glycosylation to give product **38** (79 mg, 91% yield) as a syrup after column purification (hexanes/ethyl acetate, 14:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. ^1H NMR (600 MHz, CDCl_3) δ : 7.47 – 7.09 (m, 24H, Ph), 5.71 (s, 1H, H-1), 4.96 (d, J = 11.4 Hz, 1H, Bn), 4.93 (d, J = 10.8 Hz, 1H, Bn), 4.90 (d, J = 10.8 Hz, 1H, Bn), 4.83 (d, J = 3.6 Hz, 1H, H-1'), 4.76 (d, J = 10.8 Hz, 1H, Bn), 4.72 – 4.63 (m, 4H, Bn), 4.42 – 4.35 (m, 3H, H-2, H-3, H-5), 4.01 (t, J = 9.6 Hz, 1H, H-3'), 3.90 (dd, J = 11.4, 5.4 Hz, 1H, H-6a), 3.81 (dd, J = 11.4, 4.2 Hz, 1H, H-6a'), 3.77 (dd, J = 11.4, 1.8 Hz, 1H, H-6b'), 3.76 – 3.68 (m, 2H, H-5', H-4), 3.68 (dd, J = 11.4, 1.8 Hz, 1H, H-6b), 3.59 (t, J = 9.6 Hz, 1H, H-4'), 3.50 (dd, J = 9.6, 3.6 Hz, 1H, H-2'), 2.18 (s, 3H, PhCH_3), 1.46 (s, 3H, CCH_3), 1.39 (s, 3H, CCH_3), 0.90 (s, 9H, *t*Bu), 0.05 (s, 6H, SiCH_3). ^{13}C NMR (150 MHz, CDCl_3) δ : 138.88, 138.83, 138.72, 138.24, 137.69, 132.28, 130.15, 129.90, 129.05, 128.34, 128.33, 128.24, 128.11, 127.99, 127.79, 127.72, 127.66, 127.54, 127.53, 127.44, 125.31, 109.51 (CH_3CCH_3), 97.36 (C-1'), 84.86 (C-1), 81.84, 80.30, 78.45, 77.66, 76.63, 76.16, 75.64, 74.95, 73.03, 72.33, 71.59, 69.86, 66.67, 62.23, 27.90, 26.55, 25.98, 20.99, 18.34, -5.08, -5.38. HR ESI-TOF MS (m/z): calcd for $\text{C}_{56}\text{H}_{74}\text{NO}_{10}\text{SSi}$ [$\text{M} + \text{NH}_4$] $^+$, 980.4803; found, 980.4813.


***p*-Tolyl 2,3,4-tri-*O*-benzyl-6-*O*-*tert*-butyldimethylsilyl- α -D-glucopyranosyl-(1 \rightarrow 6)-2,3,4-tri-*O*-benzoyl-1-thio- β -D-galactopyranoside (**39**)**



Donor **3** reacted with acceptor **12** by the general procedure for glycosylation to give product **39** (96 mg, 93% yield) as a syrup after column purification (hexanes/ethyl acetate, 15:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. ^1H NMR (500 MHz, CDCl_3) δ : 7.99 (d, J = 8.0 Hz, 2H, Ph), 7.92 (d, J = 8.0 Hz, 2H, Ph), 7.76 (d, J = 8.5 Hz, 2H, Ph), 7.64 – 7.20 (m, 26H, Ph), 7.13 (d, J = 7.5 Hz, 2H, Ph), 5.93 (d, J = 3.0 Hz, 1H, H-4), 5.72 (t, J = 10.0 Hz, 1H, H-2), 5.55 (dd, J = 10.0, 3.5 Hz, 1H, H-3), 4.95 (d, J = 10.5 Hz, 1H, Bn), 4.93 – 4.88 (m, 2H, Bn, H-1), 4.81 (d, J = 11.0 Hz, 1H, Bn), 4.71 (d, J = 3.0 Hz, 1H, H-1'), 4.70 – 4.67 (m, 3H, Bn), 4.22 (t, J = 5.5 Hz, 1H, H-5), 3.98 (t, J = 9.5 Hz, 1H, H-3'), 3.92 – 3.86 (m, 2H, H-6a, H-6a'), 3.84 – 3.78 (m, 2H, H-5', H-6b'), 3.61 (t, J = 9.5 Hz, 1H, H-4'), 3.56 (dd, J = 10.0, 5.0 Hz, 1H, H-6b), 3.46 (dd, J = 10.0, 3.5 Hz, 1H, H-2'), 2.29 (s, 3H, PhCH_3), 0.87 (s, 9H, *t*Bu), 0.01 (s, 6H, SiCH_3). ^{13}C NMR (125 MHz, CDCl_3) δ : 165.44, 165.39, 165.19, 138.87, 138.63, 138.54, 138.16, 134.52, 133.44, 133.24, 133.13, 130.02, 129.82, 129.74, 129.67, 129.44, 129.10, 128.89, 128.49, 128.46, 128.44, 128.39, 128.38, 128.31, 128.22, 128.03, 127.96, 127.84, 127.81, 127.76, 127.73, 127.57, 127.53, 97.12 (C-1'), 86.27 (C-1), 81.90, 80.19, 77.47, 76.33, 75.81, 74.97, 73.16, 73.14, 71.86, 68.96, 68.06, 66.48, 62.07,

25.94, 21.24, 18.30, -5.15, -5.41. HR ESI-TOF MS (m/z): calcd for $C_{67}H_{76}NO_{13}SSi$ $[M + NH_4]^+$, 1162.4807; found, 1162.4805.

Methyl 2,3,4-tri-O-benzyl-6-O-*tert*-butyldimethylsilyl- α -D-glucopyranosyl-(1 \rightarrow 6)-2,3,4-tri-O-benzoyl- α -D-glucopyranoside (40)




40

Donor **3** reacted with acceptor **13** by the general procedure for glycosylation to give product **40** (85 mg, 90% yield) as a syrup after column purification (hexanes/ethyl acetate, 10:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. 1H NMR (500 MHz, $CDCl_3$) δ : 8.02 – 7.20 (m, 30H, Ph), 6.16 (t, J = 9.5 Hz, 1H, H-3), 5.55 (t, J = 10.0 Hz, 1H, H-4), 5.24 (dd, J = 10.0, 3.5 Hz, 1H, H-2), 5.23 (d, J = 3.5 Hz, 1H, H-1), 4.91 (d, J = 10.5 Hz, 1H, Bn), 4.89 (d, J = 10.0 Hz, 1H, Bn), 4.79 (d, J = 11.0 Hz, 1H, Bn), 4.78 (d, J = 12.5 Hz, 1H, Bn),

4.73 (d, J = 3.5 Hz, 1H, H-1'), 4.68 – 4.63 (m, 2H, Bn), 4.36 – 4.31 (m, 1H, H-5), 4.00 (t, J = 9.5 Hz, 1H, H-3'), 3.87 (dd, J = 11.0, 7.0 Hz, 1H, H-6a), 3.78 – 3.66 (m, 3H, H-6a', 6b', H-6b), 3.61 – 3.55 (m, 2H, H-4', H-5'), 3.49 (dd, J = 10.0, 3.5 Hz, 1H, H-2'), 3.46 (s, 3H, OCH_3), 0.89 (s, 9H, tBu), 0.02 (s, 3H, $SiCH_3$), 0.01 (s, 3H, $SiCH_3$). ^{13}C NMR (125 MHz, $CDCl_3$) δ : 165.82, 165.81, 165.24, 138.84, 138.50, 133.30, 133.02, 129.93, 129.91, 129.67, 129.29, 129.12, 129.06, 128.39, 128.38, 128.36, 128.33, 128.30, 128.24, 128.11, 127.81, 127.68, 127.60, 127.53, 127.47, 96.95, 96.71, 81.70, 80.37, 77.53, 75.62, 74.74, 73.07, 72.26, 71.59, 70.65, 69.68, 68.61, 66.37, 61.97, 55.56, 25.94, 18.30, -5.17, -5.41. HR ESI-TOF MS (m/z): calcd for $C_{61}H_{72}NO_{14}Si$ $[M + NH_4]^+$, 1070.4722; found, 1070.4743.

***p*-Methoxyphenyl 2,3,4-tri-O-benzyl-6-O-*tert*-butyldimethylsilyl- α -D-glucopyranosyl-(1 \rightarrow 4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (41)**




41

Donor **3** reacted with acceptor **14** by the general procedure for glycosylation to give product **41** (62 mg, 72% yield) as a syrup after column purification (hexanes/ethyl acetate, 10:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. 1H NMR (500 MHz, $CDCl_3$) δ : 7.41 – 6.80 (m, 19H, Ph), 5.36 (t, J = 9.5 Hz, 1H, H-3), 5.20 (dd, J = 9.5, 7.5 Hz, 1H, H-2), 4.93 (d, J = 7.5 Hz, 1H, H-1),

4.88 – 4.83 (m, 2H, Bn), 4.82 (d, J = 11.0 Hz, 1H, Bn), 4.76 (d, J = 3.5 Hz, 1H, H-1'), 4.75 (d, J = 11.5 Hz, 1H, Bn), 4.66 – 4.62 (m, 2H, Bn), 4.59 (dd, J = 12.0, 2.0 Hz, 1H, H-6a), 4.31 (dd, J = 12.5, 5.0 Hz, 1H, H-6b), 3.93 – 3.86 (m, 2H, H-3', H-4), 3.81 – 3.77 (m, 4H, H-6a', $PhOCH_3$), 3.74 (dd, J = 11.5, 2.0 Hz, 1H, H-6b'), 3.70 – 3.64 (m, 2H, H-5, H-5'), 3.56 (t, J = 9.5 Hz, 1H, H-4'), 3.40 (dd, J = 10.0, 3.5 Hz, 1H, H-2'), 2.08 (s, 3H, $COCH_3$), 2.02 (s, 3H, $COCH_3$), 1.94 (s, 3H, $COCH_3$), 0.89 (s, 9H, tBu), 0.04 (s, 3H, $SiCH_3$), 0.02 (s, 3H, $SiCH_3$). ^{13}C NMR (125 MHz, $CDCl_3$) δ : 170.13, 170.04, 169.63, 155.69, 150.97, 138.63, 138.41, 138.02, 128.55, 128.43, 128.40, 128.38, 128.21, 128.11, 128.05, 127.78, 127.67, 127.66, 118.70, 114.52, 100.09 (C-1), 99.11 (C-1'), 81.17, 80.44, 77.33, 76.18, 75.77, 74.99, 73.82, 73.60, 73.41,

73.11, 71.64, 62.86, 61.89, 55.65, 25.92, 20.91, 20.78, 20.73, 18.34, -5.23, -5.43. HR ESI-TOF MS (*m/z*): calcd for C₅₂H₇₀NO₁₅Si [*M* + NH₄]⁺, 976.4515; found, 976.4533.


***p*-Tolyl 2,3,4-tri-*O*-benzyl-6-*O*-*tert*-butyldimethylsilyl- α -D-glucopyranosyl-(1 \rightarrow 4)-2-deoxy-2-phthalimido-3,6-di-*O*-benzyl-1-thio- β -D-glucopyranoside (42)**



Donor **3** reacted with acceptor **15** by the general procedure for glycosylation to give product **42** (90 mg, 88% yield) as a syrup after column purification (hexanes/ethyl acetate, 12:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. ¹H NMR (600 MHz, CDCl₃) δ : 7.75 (d, J = 6.6 Hz, 1H, Ph), 7.69 – 7.63 (m, 3H, Ph), 7.39 – 7.13 (m, 22H, Ph), 6.98 (d, J = 7.8 Hz, 2H, Ph), 6.91 – 6.76 (m,

5H, Ph), 5.45 (d, J = 10.2 Hz, 1H, H-1), 5.41 (d, J = 3.6 Hz, 1H, H-1'), 4.90 – 4.86 (m, 2H, Bn), 4.83 – 4.77 (m, 2H, Bn), 4.69 (d, J = 10.8 Hz, 1H, Bn), 4.65 – 4.56 (m, 4H, Bn), 4.50 (dd, J = 10.2, 8.4 Hz, 1H, H-3), 4.37 (d, J = 12.0 Hz, 1H, Bn), 4.32 (t, J = 10.2 Hz, 1H, H-2), 4.15 (t, J = 8.4 Hz, 1H, H-4), 4.05 (dd, J = 11.4, 3.6 Hz, 1H, H-6a), 3.98 (t, J = 9.6 Hz, 1H, H-3'), 3.87 (dd, J = 10.8, 1.2 Hz, 1H, H-6a'), 3.78 – 3.73 (m, 2H, H-5', H-6b), 3.73 – 3.69 (m, 1H, H-5), 3.68 – 3.61 (m, 2H, H-4', H-6b'), 3.47 (dd, J = 9.6, 3.6 Hz, 1H, H-2'), 2.28 (s, 3H, PhCH₃), 0.89 (s, 9H, *t*Bu), 0.02 (s, 3H, SiCH₃), 0.01 (s, 3H, SiCH₃). ¹³C NMR (150 MHz, CDCl₃) δ : 168.10, 167.35, 138.64, 138.59, 138.54, 138.15, 138.02, 137.89, 133.39, 129.51, 128.40, 128.35, 128.31, 128.26, 128.07, 128.05, 127.98, 127.89, 127.86, 127.66, 127.63, 127.59, 127.57, 127.46, 127.38, 126.94, 97.38 (C-1'), 83.31 (C-1), 81.76, 81.10, 80.16, 79.33, 77.54, 75.70, 75.62, 75.07, 73.93, 73.41, 73.21, 72.47, 69.10, 61.98, 54.58, 25.96, 21.14, 18.33, -5.09, -5.36. HR ESI-TOF MS (*m/z*): calcd for C₆₈H₇₉N₂O₁₁SSi [*M* + NH₄]⁺, 1159.5174; found, 1159.5175.

Isopropyl 2,3,4-tri-*O*-benzyl-6-*O*-*tert*-butyldimethylsilyl- α -D-glucopyranosyl-(1 \rightarrow 2)-3-*O*-benzoyl-4,6-*O*-benzylidene-1-thio- β -D-galactopyranoside (43)




Donor **3** reacted with acceptor **16** by the general procedure for glycosylation to give product **43** (76 mg, 86% yield) as a syrup after column purification (hexanes/ethyl acetate, 12:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. ¹H NMR (600 MHz, CDCl₃) δ : 8.02 – 7.98 (m, 2H, Ph), 7.53 – 7.17 (m, 21H, Ph), 7.00 – 6.90 (m, 2H, Ph), 5.75 (d, J = 3.6 Hz, 1H, H-1'), 5.48 (s, 1H, PhCH), 5.34 (dd, J = 9.6, 3.6 Hz, 1H, H-3), 4.92 (d, J = 12.0 Hz,

1H, Bn), 4.84 (d, J = 10.8 Hz, 1H, Bn), 4.74 (d, J = 9.0 Hz, 1H, H-1), 4.70 – 4.62 (m, 3H, Bn), 4.49 (d, J = 3.6 Hz, 1H, H-4), 4.45 (t, J = 9.6 Hz, 1H, H-2), 4.43 (d, J = 10.8 Hz, 1H, Bn), 4.35 (dd, J = 12.6, 1.2 Hz, 1H, H-6a), 4.03 (dd, J = 12.6, 1.8 Hz, 1H, H-6b), 3.81 (t, J = 9.6 Hz, 1H, H-3'), 3.73 – 3.69 (m, 1H, H-5'), 3.60 – 3.57 (m, 1H, H-5), 3.50 (dd, J = 11.4, 1.8 Hz, 1H, H-6a'), 3.46 (t, J = 9.6 Hz, 1H, H-4'), 3.44 (dd, J = 9.6, 3.6 Hz, 1H, H-2'), 3.42 – 3.33 (m, 1H, SCH), 3.31 (dd, J = 11.4, 3.6 Hz, 1H, H-6b'), 1.37 (d, J = 6.6 Hz, 3H, CHCH₃), 1.31 (d, J = 6.6 Hz, 3H, CHCH₃), 0.80 (s, 9H, *t*Bu), -0.06 (s, 3H, SiCH₃), -0.07 (s,

3H, SiCH₃). ¹³C NMR (150 MHz, CDCl₃) δ: 166.16, 138.88, 138.81, 138.27, 137.86, 133.14, 129.95, 129.84, 128.84, 128.29, 128.25, 128.08, 128.05, 128.02, 127.94, 127.56, 127.44, 127.13, 127.08, 126.23, 100.85 (PhCH), 96.08 (C-1'), 84.03 (C-1), 81.18, 80.11, 77.10, 75.62, 74.73, 74.15, 73.77, 73.13, 71.54, 69.89, 69.32, 69.15, 61.80, 34.43, 25.88, 24.48, 23.67, 18.26, -5.22, -5.41. HR ESI-TOF MS (*m/z*): calcd for C₅₆H₇₂NO₁₁SSi [M + NH₄]⁺, 994.4595; found, 994.4603.


***p*-Tolyl 2,3,4-tri-*O*-benzyl-6-*O*-*tert*-butyldimethylsilyl- α -D-glucopyranosyl-(1 \rightarrow 4)-6-deoxy-2,3-di-*O*-isopropylidene-1-thio- α -D-mannopyranoside (**44**)**



Donor **3** reacted with acceptor **17** by the general procedure for glycosylation to give product **44** (69 mg, 89% yield) as a syrup after column purification (hexanes/ethyl acetate, 12:1) with the stereochemistry determined by *J*_{H1',H2'} coupling constant. ¹H NMR (600 MHz, CDCl₃) δ: 7.45 – 7.26 (m, 17H, Ph), 7.13 (d, *J* = 7.8 Hz, 2H, Ph), 5.67 (d, *J* = 3.0 Hz, 1H, H-1'), 5.66 (s, 1H, H-1), 4.98 (d, *J* = 10.8 Hz, 1H, Bn), 4.88 (d, *J* =

11.4 Hz, 1H, Bn), 4.86 – 4.79 (m, 2H, Bn), 4.74 (d, *J* = 11.4 Hz, 1H, Bn), 4.67 (d, *J* = 10.8 Hz, 1H, Bn), 4.36 (dd, *J* = 7.2, 5.4 Hz, 1H, H-3), 4.32 (d, *J* = 5.4 Hz, 1H, H-2), 4.23 (dq, *J* = 9.6, 6.0 Hz, 1H, H-5), 3.93 (t, *J* = 9.6 Hz, 1H, H-3'), 3.84 (dd, *J* = 11.4, 4.2 Hz, 1H, H-6a'), 3.75 (dd, *J* = 11.4, 1.8 Hz, 1H, H-6b'), 3.70 – 3.63 (m, 2H, H-5', H-4), 3.57 (t, *J* = 9.6 Hz, 1H, H-4'), 3.54 (dd, *J* = 9.6, 3.6 Hz, 1H, H-2'), 2.33 (s, 3H, PhCH₃), 1.54 (s, 3H, CCH₃), 1.37 (s, 3H, CCH₃), 1.21 (d, *J* = 6.0 Hz, 3H, H-6), 0.87 (s, 9H, *t*Bu), 0.03 (s, 3H, SiCH₃), 0.02 (s, 3H, SiCH₃). ¹³C NMR (150 MHz, CDCl₃) δ: 138.81, 138.46, 138.12, 137.84, 132.56, 129.80, 129.57, 128.41, 128.40, 128.15, 128.07, 128.04, 127.78, 127.74, 127.61, 109.45 (CH₃CCH₃), 95.15 (C-1'), 84.14 (C-1), 81.71, 80.13, 78.56, 77.66, 77.42, 76.80, 75.85, 75.20, 72.97, 72.12, 65.58, 62.14, 28.00, 26.59, 25.94, 21.14, 18.36, 18.35, -5.15, -5.40. HR ESI-TOF MS (*m/z*): calcd for C₄₉H₆₈NO₉SSi [M + NH₄]⁺, 874.4384; found, 874.4390.


Diosgenyl 2,3,4-tri-*O*-benzyl-6-*O*-*tert*-butyldimethylsilyl- α -D-glucopyranoside (45**)**



Donor **3** reacted with acceptor **18** by the general procedure for glycosylation to give product **45** (80 mg, 92% yield) as a syrup after column purification (hexanes/ethyl acetate, 25:1) with the stereochemistry determined by *J*_{H1,H2} coupling constant. ¹H NMR (600 MHz, CDCl₃) δ: 7.40 – 7.13 (m, 15H, Ph), 5.35 – 5.31 (m, 1H), 5.01 (d, *J* = 10.8 Hz, 1H, Bn), 4.92 (d, *J* = 3.6 Hz, 1H, H-1), 4.90 (d, *J* = 10.8 Hz, 1H, Bn), 4.83 (d, *J* = 10.8 Hz, 1H, Bn), 4.78 (d, *J* = 12.0 Hz, 1H, Bn), 4.69 – 4.63 (m, 2H, Bn), 4.42 (q, *J* = 7.2 Hz, 1H), 4.03 (t, *J* = 9.6 Hz, 1H), 3.82 – 3.72 (m, 3H), 3.54 – 3.47 (m, 4H), 3.39 (t, *J* = 11.4 Hz, 1H), 2.48 – 2.41 (m, 1H), 2.31 – 2.25 (m, 1H), 2.05 – 1.42 (m, 15H), 1.35 – 0.92 (m, 13H), 0.89 (s, 9H, *t*Bu), 0.83 – 0.78 (m, 6H), 0.05 (s, 3H, SiCH₃), 0.04 (s, 3H, SiCH₃). ¹³C NMR (150 MHz, CDCl₃) δ: 140.83, 138.90, 138.43, 138.33, 129.02, 128.44, 128.40, 128.22, 128.10, 128.06, 127.98, 127.82, 127.74, 127.59, 125.29, 121.44,

109.27, 93.96 (C-1), 82.12, 80.83, 80.24, 78.03, 77.26, 77.05, 76.83, 75.80, 75.64, 75.11, 73.07, 71.64, 66.84, 62.46, 62.11, 56.52, 50.04, 41.61, 40.27, 39.79, 37.05, 36.95, 32.08, 31.86, 31.44, 31.40, 30.31, 28.81, 27.25, 25.98, 21.48, 20.86, 19.46, 18.33, 17.16, 16.31, 14.56, -5.11, -5.34. HR ESI-TOF MS (m/z): calcd for $C_{60}H_{88}NO_8Si$ [$M + NH_4$] $^+$, 978.6279; found, 978.6285.


3-Azidopropyl 6-O-benzoyl-2,3,4-tri-O-benzyl- α -D-glucopyranoside (46)



Donor **4** reacted with acceptor **10** by the general procedure for glycosylation to give product **46** (50 mg, 87% yield) as a syrup after column purification (hexanes/ethyl acetate, 9:1) with the stereochemistry determined by $J_{H1,H2}$ coupling constant. 1H NMR (600 MHz, $CDCl_3$) δ : 8.02 – 7.98 (m, 2H, Ph), 7.58 – 7.22 (m, 18H, Ph), 5.02 (d, J = 10.8 Hz, 1H, Bn),

4.92 (d, J = 10.8 Hz, 1H, Bn), 4.85 (d, J = 10.8 Hz, 1H, Bn), 4.80 (d, J = 12.0 Hz, 1H, Bn), 4.73 (d, J = 3.6 Hz, 1H, H-1), 4.65 (d, J = 12.0 Hz, 1H, Bn), 4.62 (d, J = 10.8 Hz, 1H, Bn), 4.55 (dd, J = 12.0, 2.4 Hz, 1H, H-6a), 4.47 (dd, J = 12.0, 4.8 Hz, 1H, H-6b), 4.04 (t, J = 9.6 Hz, 1H, H-3), 3.97 – 3.92 (m, 1H, H-5), 3.79 – 3.72 (m, 1H, OCH_2CH_2), 3.61 (t, J = 9.6 Hz, 1H, H-4), 3.58 (dd, J = 9.6, 3.6 Hz, 1H, H-2), 3.49 – 3.33 (m, 3H, CH_2N_3 , OCH_2CH_2), 1.97 – 1.83 (m, 2H, $CH_2CH_2CH_2$). ^{13}C NMR (150 MHz, $CDCl_3$) δ : 166.19, 138.50, 138.11, 137.68, 133.09, 129.84, 129.63, 128.51, 128.49, 128.38, 128.13, 128.08, 127.98, 127.95, 127.77, 97.00 (C-1), 81.99, 80.25, 77.62, 75.91, 75.27, 73.34, 69.01, 64.79, 63.43, 48.26, 28.82. HR ESI-TOF MS (m/z): calcd for $C_{37}H_{43}N_4O_7$ [$M + NH_4$] $^+$, 655.3132; found, 655.3134.


p-Tolyl 6-O-benzoyl-2,3,4-tri-O-benzyl- α -D-glucopyranosyl-(1 \rightarrow 6)-4-O-benzyl-2,3-di-O-isopropylidene-1-thio- α -D-mannopyranoside (47)



Donor **4** reacted with acceptor **11** by the general procedure for glycosylation to give product **47** (77 mg, 90% yield) as a syrup after column purification (hexanes/ethyl acetate, 10:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. 1H NMR (600 MHz, $CDCl_3$) δ : 8.00 (d, J = 8.4 Hz, 2H, Ph), 7.59 – 6.99 (m, 27H, Ph), 5.71 (s, 1H, H-1), 5.00 – 4.91 (m, 3H, Bn), 4.82 (d, J = 3.6 Hz, 1H, H-1'), 4.78 (d, J = 10.2 Hz, 1H,

Bn), 4.69 (s, 2H, Bn), 4.65 – 4.61 (m, 2H, Bn), 4.50 (dd, J = 12.0, 2.4 Hz, 1H, H-6a'), 4.46 (dd, J = 12.0, 4.2 Hz, 1H, H-6b'), 4.43 – 4.34 (m, 3H, H-2, H-3, H-5), 4.03 (t, J = 9.6 Hz, 1H, H-3'), 4.02 – 3.97 (m, 1H, H-5'), 3.91 (dd, J = 11.4, 5.4 Hz, 1H, H-6a), 3.72 (dd, J = 10.2, 6.6 Hz, 1H, H-4), 3.67 – 3.61 (m, 2H, H-4', H-6b), 3.55 (dd, J = 9.6, 3.6 Hz, 1H, H-2'), 2.17 (s, 3H, $PhCH_3$), 1.47 (s, 3H, CCH_3), 1.39 (s, 3H, CCH_3). ^{13}C NMR (150 MHz, $CDCl_3$) δ : 166.22, 138.57, 138.46, 138.12, 138.02, 137.80, 133.58, 133.01, 132.33, 130.15, 129.95, 129.92, 129.91, 129.66, 128.45, 128.43, 128.41, 128.35, 128.31, 128.17, 128.00, 127.97, 127.86, 127.83, 127.80, 127.74, 127.71, 127.58, 109.56 (CH_3CCH_3), 97.40 (C-1'), 84.88 (C-1), 81.82, 80.03, 78.43, 77.58, 76.59, 76.05, 75.78, 75.19, 73.02, 72.40, 69.76, 68.85, 67.01, 63.43, 27.92, 26.55, 21.00. HR ESI-TOF MS (m/z): calcd for $C_{57}H_{64}NO_{11}S$ [$M + NH_4$] $^+$, 970.4200; found, 970.4224.

***p*-Tolyl 6-O-benzoyl-2,3,4-tri-O-benzyl- α -D-glucopyranosyl-(1 \rightarrow 6)-2,3,4-tri-O-benzoyl-1-thio- β -D-galactopyranoside (48)**




48

Donor **4** reacted with acceptor **12** by the general procedure for glycosylation to give product **48** (95 mg, 94% yield) as a syrup after column purification (hexanes/ethyl acetate, 10:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. ^1H NMR (500 MHz, CDCl_3) δ : 8.06 (d, J = 7.5 Hz, 2H, Ph), 8.02 (d, J = 8.0 Hz, 2H, Ph), 7.89 (d, J = 8.5 Hz, 2H, Ph), 7.89 (d, J = 8.5 Hz, 2H, Ph), 7.63 – 7.11 (m, 31H, Ph), 7.13 (d, J = 7.5 Hz, 2H, Ph), 5.96 (d, J =

3.5 Hz, 1H, H-4), 5.76 (t, J = 10.0 Hz, 1H, H-2), 5.59 (dd, J = 10.0, 3.5 Hz, 1H, H-3), 5.02 (d, J = 10.5 Hz, 1H, Bn), 4.96 (d, J = 8.0 Hz, 1H, H-1), 4.94 (d, J = 9.5 Hz, 1H, Bn), 4.85 (d, J = 9.5 Hz, 1H, Bn), 4.74 (d, J = 3.5 Hz, 1H, H-1'), 4.71 (s, 2H, Bn), 4.67 (d, J = 10.5 Hz, 1H, Bn), 4.60 (dd, J = 12.0, 3.5 Hz, 1H, H-6a'), 4.56 (dd, J = 12.0, 4.0 Hz, 1H, H-6b'), 4.28 (t, J = 6.0 Hz, 1H, H-5), 4.21 – 4.17 (m, 1H, H-5'), 4.06 (t, J = 9.5 Hz, 1H, H-3'), 3.96 (dd, J = 9.5, 6.0 Hz, 1H, H-6a), 3.65 (t, J = 9.5 Hz, 1H, H-4'), 3.62 – 3.57 (m, 2H, H-2', H-6b), 2.30 (s, 3H, PhCH_3). ^{13}C NMR (125 MHz, CDCl_3) δ : 166.24, 165.49, 165.43, 165.21, 138.63, 138.62, 137.97, 137.85, 134.52, 133.50, 133.28, 133.18, 133.08, 130.00, 129.90, 129.84, 129.75, 129.74, 129.73, 129.43, 128.95, 128.87, 128.52, 128.49, 128.42, 128.27, 128.25, 128.06, 127.98, 127.84, 127.74, 127.57, 97.13 (C-1'), 86.43 (C-1), 81.96, 80.01, 77.50, 76.27, 75.94, 75.22, 73.24, 73.14, 69.27, 68.96, 68.07, 66.95, 63.46, 21.26. HR ESI-TOF MS (m/z): calcd for $\text{C}_{68}\text{H}_{66}\text{NO}_{14}\text{S}$ [$\text{M} + \text{NH}_4$] $^+$, 1152.4204; found, 1152.4208.

Methyl 6-O-benzoyl-2,3,4-tri-O-benzyl- α -D-glucopyranosyl-(1 \rightarrow 6)-2,3,4-tri-O-benzoyl- α -D-glucopyranoside (49)




49

Donor **4** reacted with acceptor **13** by the general procedure for glycosylation to give product **49** (86 mg, 92% yield) as a syrup after column purification (hexanes/ethyl acetate, 8:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. ^1H NMR (500 MHz, CDCl_3) δ : 8.06 – 7.21 (m, 35H, Ph), 6.17 (t, J = 10.0 Hz, 1H, H-3), 5.52 (t, J = 10.0 Hz, 1H, H-4), 5.26 (d, J = 3.5 Hz, 1H, H-1), 5.19 (dd, J = 10.0, 3.5 Hz, 1H, H-2), 5.00 (d, J = 11.0 Hz, 1H, Bn), 4.95 (d, J = 11.0 Hz, 1H, Bn), 4.85 (d, J = 11.0 Hz, 1H, Bn), 4.81 (d, J = 12.5 Hz, 1H, Bn),

4.76 (d, J = 3.5 Hz, 1H, H-1'), 4.68 (d, J = 12.5 Hz, 1H, Bn), 4.64 (d, J = 11.0 Hz, 1H, Bn), 4.51 (d, J = 12.0 Hz, 1H, H-6a'), 4.38 – 4.30 (m, 2H, H-5, H-6b'), 4.12 – 4.05 (m, 2H, H-3', H-5'), 3.90 (dd, J = 11.0, 6.5 Hz, 1H, H-6a), 3.61 – 3.55 (m, 3H, H-2', H-4', H-6b), 3.49 (s, 3H, OCH_3). ^{13}C NMR (125 MHz, CDCl_3) δ : 166.13, 165.80, 165.74, 165.23, 138.62, 138.31, 138.06, 133.39, 133.32, 133.06, 133.02, 130.02, 129.94, 129.90, 129.69, 129.29, 129.14, 128.98, 128.49, 128.46, 128.43, 128.41, 128.27, 128.15, 127.92, 127.90, 127.85, 127.77, 127.69, 96.88, 96.82, 81.73, 80.28, 77.64, 75.77, 74.94, 73.15, 72.19, 70.62, 69.55, 68.98, 68.59, 66.58, 63.43, 55.64. HR ESI-TOF MS (m/z): calcd for $\text{C}_{62}\text{H}_{62}\text{NO}_{15}$ [$\text{M} + \text{NH}_4$] $^+$, 1060.4119; found, 1060.4149.


***p*-Methoxyphenyl 6-*O*-benzoyl-2,3,4-tri-*O*-benzyl- α -D-glucopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-acetyl- β -D-glucopyranoside (50)**



Donor **4** reacted with acceptor **14** by the general procedure for glycosylation to give product **50** (64 mg, 75% yield) as a syrup after column purification (hexanes/ethyl acetate, 8:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. ^1H NMR (500 MHz, CDCl_3) δ : 8.04 – 6.79 (m, 24H, Ph), 5.38 (t, J = 9.5 Hz, 1H, H-3), 5.18 (dd, J = 9.5, 8.0 Hz, 1H, H-2), 4.93 (d, J = 7.5 Hz, 1H, H-1), 4.91

(d, J = 11.0 Hz, 1H, Bn), 4.88 (d, J = 11.0 Hz, 1H, Bn), 4.84 (d, J = 10.5 Hz, 1H, Bn), 4.82 (d, J = 3.5 Hz, 1H, H-1'), 4.76 (d, J = 12.0 Hz, 1H, Bn), 4.66 (d, J = 12.0 Hz, 1H, Bn), 4.62 – 4.57 (m, 2H, Bn, H-6a), 4.54 (dd, J = 12.0, 2.0 Hz, 1H, H-6a'), 4.42 (dd, J = 12.0, 4.5 Hz, 1H, H-6b'), 4.28 (dd, J = 12.0, 5.0 Hz, 1H, H-6b), 4.05 – 4.00 (m, 1H, H-5'), 3.97 (t, J = 9.5 Hz, 1H, H-3'), 3.89 (t, J = 9.5 Hz, 1H, H-4), 3.78 (s, 3H, PhOCH_3), 3.72 – 3.67 (m, 1H, H-5), 3.57 (t, J = 9.5 Hz, 1H, H-4'), 3.49 (dd, J = 10.0, 3.5 Hz, 1H, H-2'), 2.09 (s, 3H, COCH_3), 1.99 (s, 3H, COCH_3), 1.95 (s, 3H, COCH_3). ^{13}C NMR (125 MHz, CDCl_3) δ : 170.13, 170.05, 169.57, 166.08, 155.72, 150.92, 138.36, 137.82, 137.66, 133.10, 129.84, 129.66, 128.64, 128.51, 128.45, 128.40, 128.23, 128.19, 128.11, 128.00, 127.90, 127.82, 118.73, 114.53, 100.03 (C-1), 98.73 (C-1'), 81.23, 80.33, 77.48, 76.34, 75.86, 75.12, 73.86, 73.50, 73.37, 71.56, 70.42, 63.38, 62.56, 55.65, 20.93, 20.77, 20.72. HR ESI-TOF MS (m/z): calcd for $\text{C}_{53}\text{H}_{56}\text{O}_{16}\text{Na}$ [$\text{M} + \text{Na}$] $^+$, 971.3466; found, 971.3496.

***p*-Tolyl 6-*O*-benzoyl-2,3,4-tri-*O*-benzyl- α -D-glucopyranosyl-(1 \rightarrow 4)-2-deoxy-2-phthalimido-3,6-di-*O*-benzyl-1-thio- β -D-glucopyranoside (51)**




Donor **4** reacted with acceptor **15** by the general procedure for glycosylation to give product **51** (86 mg, 84% yield) as a syrup after column purification (hexanes/ethyl acetate, 11:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. ^1H NMR (600 MHz, CDCl_3) δ : 8.12 – 8.05 (m, 1H, Ph), 8.02 – 7.95 (m, 2H, Ph), 7.76 – 7.12 (m, 28H, Ph), 7.02 – 6.71 (m, 7H, Ph), 5.41 (d, J = 10.2 Hz, 1H, H-1), 5.36 (d, J = 3.6 Hz, 1H, H-1'), 4.98 – 4.87 (m, 2H, Bn), 4.80 – 4.74 (m, 2H, Bn), 4.63 – 4.58 (m, 3H, Bn), 4.54 – 4.51 (m, 2H, Bn), 4.48 (dd, J = 10.2, 9.0 Hz, 1H, H-3), 4.44 (dd, J = 12.0, 2.4 Hz, 1H, H-6a'), 4.39 (dd, J = 12.0, 4.8 Hz, 1H, H-6b'), 4.33 (d, J = 12.0 Hz, 1H, Bn), 4.28 (t, J = 10.2 Hz, 1H, H-2), 4.13

(t, J = 9.6 Hz, 1H, H-4), 4.11 – 4.08 (m, 1H, H-5'), 4.02 – 3.98 (m, 2H, H-3', H-6a), 3.75 (dd, J = 11.4, 1.8 Hz, 1H, H-6b), 3.69 – 3.63 (m, 1H, H-5), 3.57 (t, J = 9.6 Hz, 1H, H-4'), 3.51 (dd, J = 9.6, 3.6 Hz, 1H, H-2'), 2.27 (s, 3H, PhCH_3). ^{13}C NMR (150 MHz, CDCl_3) δ : 166.11, 138.27, 138.23, 138.16, 138.05, 137.82, 137.73, 133.64, 133.38, 133.03, 130.15, 129.90, 129.63, 129.51, 128.86, 128.47, 128.44, 128.39, 128.36, 128.23, 128.04, 127.88, 127.86, 127.72, 127.70, 127.66, 127.46, 127.43, 126.90, 126.26, 97.30 (C-1'), 83.45 (C-1), 81.71, 80.76, 79.99, 79.30, 77.70, 76.44, 75.75, 75.20, 73.94, 73.26, 73.25, 69.79, 68.76,

63.49, 54.53, 21.13. HR ESI-TOF MS (m/z): calcd for $C_{69}H_{69}N_2O_{12}S$ [$M + NH_4$] $^+$, 1149.4571; found, 1149.4579.


Isopropyl 6-O-benzoyl-2,3,4-tri-O-benzyl- α -D-glucopyranosyl-(1 \rightarrow 2)-3-O-benzoyl-4,6-O-benzylidene-1-thio- β -D-galactopyranoside (52)



Donor **4** reacted with acceptor **16** by the general procedure for glycosylation to give product **52** (74 mg, 85% yield) as a syrup after column purification (hexanes/ethyl acetate, 10:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. 1H NMR (600 MHz, $CDCl_3$) δ : 7.99 (d, J = 7.8 Hz, 2H, Ph), 7.91 (d, J = 7.8 Hz, 2H, Ph), 7.51 – 7.44 (m, 4H, Ph), 7.43 – 7.39 (m, 2H, Ph), 7.36 – 7.14 (m, 18H, Ph), 6.91 – 6.87 (m, 2H, Ph), 5.80 (d, J = 3.6 Hz, 1H, H-1'), 5.50

(s, 1H, PhCH), 5.40 (dd, J = 9.6, 3.6 Hz, 1H, H-3), 4.95 (d, J = 11.4 Hz, 1H, Bn), 4.90 (d, J = 10.8 Hz, 1H, Bn), 4.76 (d, J = 9.0 Hz, 1H, H-1), 4.71 – 4.65 (m, 3H, Bn), 4.49 (d, J = 4.2 Hz, 1H, H-4), 4.46 (t, J = 9.6 Hz, 1H, H-2), 4.37 – 4.30 (m, 2H, H-6a, Bn), 4.23 (d, J = 12.0 Hz, 1H, H-6a'), 4.06 – 4.02 (m, 1H, H-6b), 4.01 – 3.97 (m, 1H, H-5'), 3.90 – 3.85 (m, 2H, H-3', H-6b'), 3.61 – 3.58 (m, 1H, H-5), 3.52 (dd, J = 9.6, 3.6 Hz, 1H, H-2'), 3.48 (t, J = 9.6 Hz, 1H, H-4'), 3.39 – 3.33 (m, 1H, SCH), 1.34 (d, J = 6.6 Hz, 3H, CHCH $_3$), 1.29 (d, J = 6.6 Hz, 3H, CHCH $_3$). ^{13}C NMR (150 MHz, $CDCl_3$) δ : 166.17, 166.12, 138.50, 138.06, 137.99, 137.70, 133.38, 132.91, 129.78, 129.73, 129.69, 129.51, 128.91, 128.41, 128.35, 128.30, 128.17, 128.10, 128.09, 127.92, 127.67, 127.62, 127.42, 127.38, 126.17, 100.95 (PhCH), 95.99 (C-1'), 83.89 (C-1), 81.14, 79.88, 77.21, 75.78, 74.55, 74.48, 73.87, 73.13, 70.42, 69.37, 69.13, 68.88, 63.26, 34.57, 24.33, 23.68. HR ESI-TOF MS (m/z): calcd for $C_{57}H_{62}NO_{12}S$ [$M + NH_4$] $^+$, 984.3993; found, 984.4005.

***p*-Tolyl 6-O-benzoyl-2,3,4-tri-O-benzyl- α -D-glucopyranosyl-(1 \rightarrow 4)-6-deoxy-2,3-di-O-isopropylidene-1-thio- α -D-mannopyranoside (53)**




Donor **4** reacted with acceptor **17** by the general procedure for glycosylation to give product **53** (66 mg, 87% yield) as a syrup after column purification (hexanes/ethyl acetate, 14:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. 1H NMR (600 MHz, $CDCl_3$) δ : 8.00 (d, J = 7.8 Hz, 2H, Ph), 7.57 – 7.04 (m, 22H, Ph), 5.67 (d, J = 4.2 Hz, 1H, H-1'), 5.66 (s, 1H, H-1), 5.04 (d, J = 10.2 Hz, 1H, Bn), 4.92 (d, J = 10.8 Hz, 1H, Bn), 4.88 – 4.82 (m, 2H, Bn), 4.75 (d, J = 11.4 Hz, 1H, Bn), 4.61 (d, J = 10.8 Hz, 1H, Bn), 4.51 (dd, J = 12.0, 2.4 Hz, 1H, H-6a'), 4.46 (dd, J = 12.0, 4.8 Hz, 1H, H-6b'), 4.35 (t, J = 6.0 Hz, 1H, H-3), 4.31 (d, J = 5.4 Hz, 1H, H-2), 4.28 – 4.21 (m, 1H, H-5), 4.08 – 4.03 (m, 1H, H-5'), 4.01 (t, J = 9.6 Hz, 1H, H-3'), 3.70 – 3.57 (m, 3H, H-2', H-4, H-4'), 2.34 (s, 3H, PhCH $_3$), 1.44 (s, 3H, CCH $_3$), 1.34 (s, 3H, CCH $_3$), 1.26

(d, J = 6.0 Hz, 3H, H-6). ^{13}C NMR (150 MHz, $CDCl_3$) δ : 166.25, 138.53, 137.95, 137.94, 137.68, 133.05, 132.64, 129.85, 129.79, 129.71, 129.65, 129.46, 128.49, 128.38, 128.19, 128.08, 127.99, 127.90, 127.77,

109.53 (CH₃CCH₃), 95.29 (C-1'), 84.18 (C-1), 81.75, 79.90, 78.35, 78.33, 77.72, 76.69, 75.94, 75.33, 73.05, 69.36, 65.39, 63.73, 27.93, 26.48, 21.17, 18.37. HR ESI-TOF MS (*m/z*): calcd for C₅₀H₅₈NO₁₀S [M + NH₄]⁺, 864.3781; found, 864.3783.


Diosgenyl 6-O-benzoyl-2,3,4-tri-O-benzyl- α -D-glucopyranoside (**54**)



Donor **4** reacted with acceptor **18** by the general procedure for glycosylation to give product **54** (80 mg, 93% yield) as a syrup after column purification (hexanes/ethyl acetate, 15:1): α/β = 10:1 as determined by integrations of H-1 and CH₃ signals with the stereochemistry determine by $J_{H1,H2}$ coupling constant.

α -**54**: ¹H NMR (600 MHz, CDCl₃) δ : 8.00 – 7.97 (m, 2H, Ph), 7.56 – 7.52 (m, 1H, Ph), 7.42 – 7.19 (m, 17H, Ph), 5.23 (d, J = 5.4 Hz, 1H), 5.04 (d, J = 10.8 Hz, 1H, Bn), 4.92 (d, J = 11.4 Hz, 1H, Bn), 4.91 (d, J = 3.6 Hz, 1H, H-1), 4.84 (d, J = 10.8 Hz, 1H, Bn), 4.78 (d, J = 12.0 Hz, 1H, Bn), 4.67 (d, J = 12.0 Hz, 1H, Bn), 4.61 (d, J = 10.8 Hz, 1H, Bn), 4.56 – 4.52 (m, 1H, H-6a), 4.48 – 4.40 (m, 2H, H-6b, H-4), 4.12 – 4.05 (m, 2H, H-3, H-5), 3.58 – 3.53 (m, 2H, H-2), 3.50 – 3.44 (m, 2H), 3.39 (t, J = 10.8 Hz, 1H), 2.50 – 2.40 (m, 1H), 2.33 – 2.28 (m, 1H), 2.03 – 1.40 (m, 15H), 1.35 – 0.75 (m, 19H). ¹³C NMR (150 MHz, CDCl₃) δ : 166.26, 140.59, 138.63, 138.10, 137.72, 132.97, 129.85, 129.71, 128.52, 128.47, 128.43, 128.41, 128.37, 128.32, 128.20, 128.15, 128.11, 128.07, 128.00, 127.97, 127.94, 127.72, 121.53, 109.27, 94.38 (C-1), 82.07, 80.80, 80.05, 77.98, 76.58, 75.89, 75.28, 73.13, 68.85, 66.84, 63.77, 62.09, 56.52, 49.99, 41.59, 40.26, 39.86, 39.76, 37.00, 36.89, 32.10, 31.85, 31.41, 31.38, 30.30, 28.80, 27.39, 20.82, 19.38, 19.35, 17.15, 16.29, 14.55. HR ESI-TOF MS (*m/z*): calcd for C₆₁H₇₈NO₉ [M + NH₄]⁺, 968.5677; found, 968.5682.


3-Azidopropyl 6-O-benzoyl-2,3-di-O-benzyl- α -D-glucopyranosyl-(1→4)-6-O-benzoyl-2,3-di-O-benzyl- α -D-glucopyranoside (**58**)



After the mixture of donor **62** (350 mg, 0.51 mmol) and freshly activated MS 4Å in anhydrous diethyl ether (20 mL) was stirred at room temperature for 1.0 h and then cooled to -78 °C, a solution of AgOTf (132 mg, 0.51 mmol) in diethyl ether (1.5 mL) was added. The mixture was stirred for 15 min, and *p*-

TolSCI (74 μ L, 0.51 mmol) was added through a microsyringe without touching the flask. Fifteen minutes later, a solution of acceptor **61** (262 mg, 0.46 mmol) in anhydrous diethyl ether (2.0 mL), which was precooled to -78°C , was added. The reaction was warmed up to room temperature slowly in 1.5 h and stirred for another 15 min, before it was cooled to -78°C again. Next, the AgOTf (118 mg, 0.46 mmol) in anhydrous diethyl ether (1.0 mL), *p*-TolSCI (66 μ L, 0.46 mmol), and precooled **10** (46 mg, 0.46 mmol) were added sequentially. The reaction mixture was warmed up to room temperature slowly and stirred for another 15 min before it was quenched with Et_3N , diluted with CH_2Cl_2 , and filtered. The filtrate was concentrated under vacuum, and the residue purified by flash silica gel column chromatography (hexanes/ethyl acetate, 8:1) to provide **63**. To the solution of **63** in acetonitrile/ CH_2Cl_2 (V/V, 1:3, 4 mL) was added triethylamine trihydrofluoride (1 mL). The reaction solution was stirred at room temperature for overnight. The mixture was diluted with ethyl acetate (20 mL) and washed with saturated aq. NaHCO_3 solution and brine, the organic layer was dried with Na_2SO_4 and concentrated. Purification of the residue on a silica gel column (hexanes/ethyl acetate, 7:1) provided product **58** (279 mg, 61% for three steps) as a syrup. ^1H NMR (600 MHz, CDCl_3) δ : 8.08 – 7.96 (m, 4H, Ph), 7.60 – 7.51 (m, 2H, Ph), 7.47 – 7.37 (m, 4H, Ph), 7.31 – 7.15 (m, 20H, Ph), 5.71 (d, J = 3.6 Hz, 1H, H-1'), 5.02 (d, J = 11.4 Hz, 1H, Bn), 4.89 (d, J = 10.8 Hz, 1H, Bn), 4.82 – 4.75 (m, 2H, Bn), 4.72 (d, J = 3.6 Hz, 1H, H-1), 4.71 (dd, J = 12.0, 2.4 Hz, 1H, H-6a), 4.65 (d, J = 12.0 Hz, 1H, Bn), 4.61 (d, J = 12.0 Hz, 1H, Bn), 4.58 (dd, J = 12.0, 3.6 Hz, 1H, H-6a'), 4.55 – 4.52 (m, 3H, Bn, H-6b), 4.28 (dd, J = 12.0, 2.4 Hz, 1H, H-6b'), 4.10 (t, J = 9.0 Hz, 1H, H-3'), 4.09 – 4.05 (m, 1H, H-5), 4.00 (dd, J = 9.6, 8.4 Hz, 1H, H-4), 3.90 – 3.87 (m, 1H, H-5'), 3.86 (t, J = 9.6 Hz, 1H, H-3), 3.77 – 3.71 (m, 1H, OCH_2CH_2), 3.58 (dd, J = 9.0, 3.6 Hz, 1H, H-2), 3.51 (t, J = 9.6 Hz, 1H, H-4'), 3.47 – 3.38 (m, 4H, H-2', OCH_2CH_2 , N_3CH_2), 2.77 (s, 1H, OH), 1.94 – 1.87 (m, 2H, $\text{CH}_2\text{CH}_2\text{CH}_2$). ^{13}C NMR (150 MHz, CDCl_3) δ : 166.87, 166.15, 138.83, 138.40, 137.83, 137.76, 133.25, 133.15, 129.82, 129.71, 129.67, 129.64, 128.51, 128.48, 128.34, 128.32, 128.31, 128.25, 128.02, 128.00, 127.97, 127.83, 127.65, 127.58, 127.13, 126.57, 97.12 (C-1'), 96.58 (C-1), 81.46, 80.86, 80.41, 78.91, 75.60, 74.17, 73.60, 73.37, 73.22, 71.12, 70.20, 68.39, 64.89, 63.79, 63.42, 48.25, 28.78. HR ESI-TOF MS (m/z): calcd for $\text{C}_{57}\text{H}_{59}\text{N}_3\text{O}_{13}\text{Na}$ [$\text{M} + \text{Na}$] $^+$, 1016.3946; found, 1016.3933.


3-Azidopropyl 4,6-di-O-[6-O-benzoyl-2,3,4-tri-O-benzyl- α -D-glucopyranosyl-(1 \rightarrow 4)-6-O-benzoyl-2,3-di-O-benzyl- α -D-glucopyranosyl]-2,3-di-O-benzyl- α -D-glucopyranosyl-(1 \rightarrow 4)-6-O-benzoyl-2,3-di-O-benzyl- α -D-glucopyranosyl-(1 \rightarrow 4)-6-O-benzoyl-2,3-di-O-benzyl- α -D-glucopyranoside (56)



After the mixture of donor **4** (128 mg, 194 μmol) and freshly activated MS 4Å in anhydrous diethyl ether (10 mL) was stirred at room temperature for 1.0 h and then cooled to -78 °C, a solution of AgOTf (50 mg, 194 μmol) in diethyl ether (0.5 mL) was added. The mixture was stirred for 15 min, and *p*-TolSCI (28 μL , 194 μmol) was added through a microsyringe without touching the flask. Fifteen minutes later, a solution of precooled acceptor **61** (100 mg, 176 μmol) in anhydrous diethyl ether (1.5 mL) was added. The reaction was warmed up to room temperature slowly in 1.5 h and stirred for another 15 min, before it was cooled to -78 °C. Next, the AgOTf (45 mg, 176 μmol) in anhydrous diethyl ether (0.5 mL), *p*-TolSCI (25 μL , 176 μmol), and precooled **59** (37 mg, 80 μmol) were added sequentially. The reaction mixture was warmed up to room temperature slowly in 1.5 h and stirred for another 15 min before it was cooled to -78 °C again. Then, the AgOTf (21 mg, 80 μmol) in anhydrous diethyl ether (0.2 mL), *p*-TolSCI (12 μL , 80 μmol), and precooled **58** (79 mg, 80 μmol) were added in the same sequence. The reaction was warmed up to room temperature slowly and stirred for another 15 min before it was quenched with Et₃N, diluted with CH₂Cl₂, and filtered. The filtrate was concentrated under vacuum, and the residue purified by flash silica gel column chromatography (hexanes/ethyl acetate, 8:1) to provide **56** (143 mg, 54% yield for one-pot three step reactions) as a white syrup. ¹H NMR (600 MHz, CDCl₃) δ : 8.16 – 8.09 (m, 3H, Ph), 8.08 – 7.99 (m, 4H, Ph), 7.95 – 7.89 (m, 4H, Ph), 7.58 – 6.85 (m, 99H, Ph), 5.86 (d, *J* = 3.6 Hz, 1H, H-1^A), 5.68 (d, *J* = 3.6 Hz, 1H, H-1^B), 5.62 (d, *J* = 3.6 Hz, 1H, H-1^C), 5.59 (d, *J* = 3.6 Hz, 1H, H-1^D), 5.36 (d, *J* = 3.0 Hz, 1H, H-1^E), 5.29 (d, *J* = 3.6 Hz, 1H, H-1^F), 5.17 (d, *J* = 10.8 Hz, 1H, Bn), 5.05 – 4.97 (m, 2H), 4.90 – 4.79 (m, 7H), 4.78 – 4.74 (m, 3H), 4.72 (d, *J* = 3.6 Hz, 1H, H-1^G), 4.70 – 4.65 (m, 4H), 4.65 – 4.58 (m, 4H), 4.58 – 4.43 (m, 13H), 4.41 – 4.29 (m, 5H), 4.26 – 4.19 (m, 4H), 4.19 – 4.03 (m, 10H), 4.02 – 3.88 (m, 8H), 3.80 (d, *J* = 10.2 Hz, 1H), 3.75 – 3.69 (m, 1H), 3.65 (t, *J* = 9.6 Hz, 1H), 3.62 – 3.57 (m, 3H), 3.57 – 3.35 (m, 10H), 3.16 (dd, *J* = 9.6, 3.6 Hz, 1H), 1.93 – 1.81 (m, 2H). ¹³C NMR (150 MHz, CDCl₃) δ : 166.12, 166.04, 165.96, 165.86, 165.73, 139.17, 138.89, 138.73, 138.63, 138.40, 138.15, 137.94, 137.90,


137.89, 137.82, 137.71, 137.68, 137.57, 133.45, 133.30, 133.18, 133.04, 132.88, 132.84, 130.04, 129.97, 129.95, 129.91, 129.84, 129.81, 129.76, 129.73, 129.70, 129.66, 129.64, 129.62, 129.58, 128.66, 128.54, 128.52, 128.49, 128.45, 128.40, 128.38, 128.34, 128.32, 128.31, 128.27, 128.25, 128.22, 128.18, 128.15, 128.08, 128.04, 128.00, 127.98, 127.95, 127.94, 127.92, 127.85, 127.75, 127.74, 127.71, 127.67, 127.53, 127.50, 127.48, 127.42, 127.37, 127.25, 127.23, 127.20, 127.16, 127.03, 126.85, 126.81, 126.72, 126.68, 126.50, 126.26, 96.96 (C-1^D), 96.93 (C-1^A), 96.90 (C-1^B), 96.71 (C-1^E), 96.63 (C-1^G), 96.54 (C-1^C), 96.25 (C-1^F), 81.88, 81.62, 81.34, 81.21, 80.85, 80.31, 80.19, 79.91, 79.64, 79.35, 79.05, 78.88, 78.26, 77.63, 77.57, 75.75, 75.63, 75.33, 74.96, 74.90, 74.77, 74.40, 73.85, 73.72, 73.57, 73.34, 73.26, 72.49, 72.30, 72.24, 71.95, 69.97, 69.80, 69.44, 69.38, 68.62, 67.87, 64.89, 63.98, 63.86, 63.61, 63.31, 63.03, 62.97, 48.28, 28.81. HR ESI-TOF MS (m/z): calcd for C₁₉₉H₂₀₁N₄O₄₂ [M + NH₄]⁺, 3318.3715; found, 3318.3709.

3-Aminopropyl 4,6-di-O-[α-D-glucopyranosyl-(1→4)-α-D-glucopyranosyl]-α-D-glucopyranosyl-(1→4)-α-D-glucopyranoside (55)




To a solution of **56** (50 mg, 15 μmol) in CH₃OH/CH₂Cl₂ (V/V, 3:1, 10 mL) was added sodium methoxide (1 mL, 1.0 M in methanol). The reaction mixture was stirred at room temperature for 3 hours and then neutralized by Amberlite® IR120 hydrogen form. The resin was removed by filtration and the filtrate was concentrated under vacuum. The residue was dissolved in a mixed solvent of CH₃OH/CH₂Cl₂ (V/V, 9:1, 10 mL), and a catalytic amount of 20 wt% Pd(OH)₂/C was added. The reaction mixture was stirred for 36 h under H₂ atmosphere in 50 psi. The progress of the reaction was monitored by MALDI-TOF mass spectrometer. Upon completion, the reaction mixture was filtrated and the filtrate was purified on a Sephadex G-25 gel column with H₂O as the eluent to produce the synthetic target **55** (16 mg, 85% over two steps) as a white foam. ¹H NMR (600 MHz, D₂O) δ: 5.23 (d, *J* = 4.2 Hz, 1H, H-1^A), 5.21 (d, *J* = 3.6 Hz, 1H, H-1^B), 5.18 (d, *J* = 4.2 Hz, 1H, H-1^C), 5.16 (d, *J* = 3.6 Hz, 1H, H-1^D), 5.14 (d, *J* = 3.6 Hz, 1H, H-1^E), 4.78 (d, *J* = 3.6 Hz, 1H, H-1^F), 4.75 (d, *J* = 4.2 Hz, 1H, H-1^G), 3.87 – 3.37 (m, 42H), 3.25 – 3.21 (m, 2H), 3.04 – 2.92 (m, 2H), 1.87 – 1.78 (m, 2H). ¹³C NMR (150 MHz, D₂O) δ: 99.86 (C-1^E), 99.81 (C-1^C), 99.75 (C-1^D), 99.56 (C-1^B), 99.32 (C-1^A), 98.37 (C-1^F), 98.00 (C-1^G), 78.59, 77.65, 77.24, 76.64, 76.54, 73.37, 73.23, 73.20, 73.11, 72.88, 72.79, 72.71, 72.59, 71.69, 71.56, 71.52, 71.26, 71.23, 71.20, 71.17, 71.00, 70.77, 70.23, 70.22, 70.12, 69.16, 69.15, 67.32, 65.75, 60.53, 60.43, 60.36, 60.34, 60.32, 60.23, 37.67, 26.37. HR ESI-TOF MS (m/z): calcd for C₄₅H₈₀NO₃₆ [M + H]⁺, 1210.4460, found, 1210.4484.

***p*-Tolyl 6-*O*-benzoyl-2,3,4-tri-*O*-benzyl- α -D-glucopyranosyl-(1 \rightarrow 4)-6-*O*-benzoyl-2,3-di-*O*-benzyl- α -D-glucopyranosyl-(1 \rightarrow 6)-2,3-di-*O*-benzyl-1-thio- β -D-glucopyranoside (**64**)**



Donor **60** (300 mg, 0.27 mmol) reacted with acceptor **59** (115 mg, 0.25 mmol) by the general procedure for glycosylation to give product **64** (286 mg, 80%) as a syrup after column purification (hexanes/ethyl acetate, 6:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. ^1H NMR (600 MHz, CDCl_3) δ : 8.04 (d, J = 8.4 Hz, 2H, Ph), 7.97 (d, J = 8.4 Hz, 2H, Ph), 7.57 – 6.96 (m, 45H, Ph), 5.60 (d, J = 3.6 Hz, 1H, H-1''), 5.01 (d, J = 11.4 Hz, 1H, Bn), 4.87 (d, J = 3.0 Hz, 1H, H-1'), 4.93 – 4.80 (m, 6H, Bn), 4.76 (d, J = 10.8 Hz, 1H, Bn), 4.72 – 4.52 (m, 9H, H-1, H-6a', 6b', Bn), 4.39 (dd, J = 12.0, 1.8 Hz, 1H, H-6a''), 4.33 (dd, J = 12.0, 3.6 Hz, 1H, H-6b''), 4.20 – 4.04 (m, 2H, H-3', H-5'), 4.04 – 3.94 (m, 4H, H-3'', H-4', H-5'', H-6a), 3.73 (t, J = 9.6 Hz, 1H, H-4), 3.62 – 3.57 (m, 3H, H-2', H-4'', H-6b), 3.54 (t, J = 9.0 Hz, 1H, H-3), 3.51 – 3.46 (m, 2H, H-5, H-2''), 3.33 (t, J = 9.6 Hz, 1H, H-2), 3.06 – 2.98 (m, 1H, OH), 2.25 (s, 3H, PhCH_3). ^{13}C NMR (150 MHz, CDCl_3) δ : 166.13, 165.96, 138.95, 138.60, 138.34, 138.06, 137.87, 137.80, 137.77, 133.13, 132.95, 132.64, 129.92, 129.88, 129.78, 129.76, 129.72, 129.66, 128.55, 128.52, 128.51, 128.47, 128.44, 128.41, 128.36, 128.33, 128.31, 128.25, 128.18, 127.96, 127.92, 127.85, 127.81, 127.78, 127.68, 127.57, 127.52, 127.03, 126.56, 97.35 (C-1''), 97.01 (C-1'), 88.28 (C-1), 86.12, 81.70, 81.29, 80.28, 80.16, 79.48, 77.63, 77.26, 75.74, 75.49, 75.35, 75.02, 74.62, 74.31, 73.44, 72.94, 72.13, 70.04, 68.41, 68.07, 63.82, 63.25, 21.10. HR ESI-TOF MS (m/z): calcd for $\text{C}_{88}\text{H}_{92}\text{NO}_{17}\text{S}$ [$\text{M} + \text{NH}_4$] $^+$, 1466.6086; found, 1466.6102.



***p*-Tolyl 4,6-di-*O*-[6-*O*-benzoyl-2,3,4-tri-*O*-benzyl- α -D-glucopyranosyl-(1 \rightarrow 4)-6-*O*-benzoyl-2,3-di-*O*-benzyl- α -D-glucopyranosyl]-2,3-di-*O*-benzyl-1-thio- β -D-glucopyranoside (**57**)**







Donor **60** (180 mg, 0.16 mmol) reacted with acceptor **64** (214 mg, 0.15 mmol) by the general procedure for glycosylation to give product **57** (316 mg, 88%) as a syrup after column purification



(hexanes/ethyl acetate, 8:1) with the stereochemistry determined by $J_{H1',H2'}$ coupling constant. ^1H NMR (600 MHz, CDCl_3) δ : 8.05 (d, $J = 7.8$ Hz, 2H, Ph), 8.01 (d, $J = 7.8$ Hz, 2H, Ph), 7.94 (d, $J = 8.4$ Hz, 4H, Ph), 7.53 – 6.91 (m, 76H, Ph), 5.63 (d, $J = 3.6$ Hz, 1H, H-1^A), 5.58 (d, $J = 3.6$ Hz, 1H, H-1^B), 5.36 (d, $J = 3.0$ Hz, 1H, H-1^C), 5.24 (d, $J = 3.0$ Hz, 1H, H-1^D), 5.09 (d, $J = 11.4$ Hz, 1H, Bn), 4.95 (d, $J = 11.4$ Hz, 1H, Bn), 4.90 – 4.64 (m, 13H, Bn), 4.68 – 4.44 (m, 12H, H-1^E, Bn), 4.42 – 4.16 (m, 8H), 4.15 – 3.83 (m, 11H), 3.69 (t, $J = 8.4$ Hz, 1H), 3.60 (t, $J = 9.6$ Hz, 1H, H-3^E), 3.58 – 3.52 (m, 3H), 3.52 – 3.39 (m, 3H), 3.23 (t, $J = 9.6$ Hz, 1H, H-2^E), 2.23 (s, 3H, PhCH_3). ^{13}C NMR (150 MHz, CDCl_3) δ : 166.03, 165.95, 165.90, 165.89, 138.92, 138.68, 138.39, 138.31, 138.06, 137.89, 137.86, 137.85, 137.82, 137.72, 137.71, 137.54, 133.16, 133.03, 132.94, 132.88, 132.76, 130.89, 130.11, 129.96, 129.93, 129.89, 129.78, 129.73, 129.70, 129.66, 129.66, 129.62, 128.81, 128.46, 128.41, 128.38, 128.36, 128.30, 128.26, 128.22, 128.20, 128.13, 128.08, 128.05, 127.99, 127.93, 127.88, 127.85, 127.78, 127.68, 127.64, 127.61, 127.55, 127.51, 127.47, 127.45, 127.35, 127.08, 127.00, 126.96, 126.86, 126.50, 126.38, 97.56 (C-1^B), 97.14 (C-1^A), 96.78 (C-1^C), 96.21 (C-1^D), 88.33 (C-1^E), 85.54, 81.77, 81.64, 81.19, 80.84, 80.54, 80.27, 79.84, 79.43, 79.31, 78.36, 77.55, 75.70, 75.66, 75.29, 75.22, 75.05, 74.91, 74.19, 73.88, 73.38, 73.15, 72.56, 72.51, 70.04, 69.92, 69.53, 68.33, 65.60, 65.55, 63.79, 63.72, 63.17, 21.10. HR ESI-TOF MS (m/z): calcd for $\text{C}_{149}\text{H}_{150}\text{NO}_{29}\text{S}$ [$\text{M} + \text{NH}_4$]⁺, 2449.0014; found, 2449.0010.



II. NMR spectra of synthetic intermediates and final products














































7.937
7.925
7.504
7.491
7.477
7.464
7.388
7.377
7.374
7.363
7.354
7.352
7.346
7.343
7.333
7.329
7.320
7.316
7.308
7.304
7.296
7.285
7.273
7.263
7.259
7.249
7.217
7.205
7.197
7.190
7.186
7.177
7.174
7.161
7.149
7.082
7.070
7.057
6.992
6.980
5.614
5.608
5.482
5.077
5.060
4.931
4.913
4.885
4.867
4.745
4.729
4.718
4.702
4.619
4.599
4.532
4.514
4.344
4.324
4.196
4.179
4.176
4.059
3.863
3.812
3.613
3.574
3.494
2.400




¹H NMR
600 MHz
CDCl₃







166.09
136.55
138.32
138.16
137.54
137.09
136.85
132.85
132.82
129.95
129.93
129.72
129.50
129.22
128.66
128.48
128.43
128.34
128.26
128.18
128.11
128.06
127.94
127.74
127.71
127.58
127.51
126.47
102.31
95.88
89.10
82.07
81.74
78.73
77.58
76.93
75.92
75.88
75.35
71.13
69.88
68.86
68.68
63.00
21.21







¹³C NMR
150 MHz
CDCl₃












































































¹H-¹³C HSQC
600/150 MHz
CDCl₃






5.860
5.854

5.683
5.677
5.628
5.622
5.591
5.585



5.366
5.361
5.292
5.286

4.727
4.721








¹³C NMR
150 MHz
CDCl₃








¹H-¹H COSY
600 MHz
CDCl₃







^1H - ^{13}C HSQC
600/150 MHz
 CDCl_3









¹³C NMR
150 MHz
D₂O





55
¹H-¹³C HSQC
 600/150 MHz
 D₂O





¹H-¹³C HSQC
600/150 MHz
D₂O









64
 ^1H - ^{13}C HSQC
 600/150 MHz
 CDCl_3





64

^1H - ^1H COSY
600 MHz
 CDCl_3





^1H - ^1H COSY
600 MHz
 CDCl_3



^1H - ^{13}C HSQC
600/150 MHz
 CDCl_3